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ABBREVIATIONS
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ABSTRACT
To improve the serology of Lyme borreliosis (LB), genes for the borrelial proteins flagellin A 
(FlaA) and outer surface protein C (OspC) from three domestic borrelial species of Borrelia 
burgdorferi sensu lato were cloned and sequenced, and the respective recombinant antigens 
were evaluated in the serology of LB. Furthermore, in order to follow the effectiveness of the 
treatment of LB and to find a serological marker of disease activity, the half-lives of flagella 
IgG antibodies were evaluated during a follow-up of patients with late LB.  
 
The amino acid sequences of FlaA were highly homologous, having identity of 95% within the 
three domestic species of B. burgdorferi sensu lato. OspC was more heterogeneous, with 
protein sequence identities varying between 57 and 73% among the borrelial species studied. 
Both for FlaA and OspC, polyhistidine-tagged recombinant proteins were produced in 
Escherichia coli. Three variants of FlaA were applied in Western blot (WB) and enzyme-
linked immunosorbent assay (ELISA). For IgG serodiagnosis of neuroborreliosis (NB) and 
Lyme arthritis (LA), FlaA appeared to be a sensitive antigen. Seventy-one or 74 per cent of 
patients with NB were positive either with WB or with ELISA, respectively. The 
corresponding positivities for LA patient samples were 86 and 79%. Although the sequences of 
the three FlaA proteins were highly homologous, the immunoreactivity in Finnish patient sera 
was stronger against recombinant FlaA (rFlaA) from B. garinii and B. afzelii than against 
rFlaA from B. burgdorferi sensu stricto. In IgM serology, low sensitivity in early LB and poor 
specificity may constrain the use of FlaA to routine serodiagnosis.  
 
For OspC, a biotinylated antigen on streptavidin-coated plates in ELISA was used. In IgM 
ELISA, 30 and 35% of patient samples of erythema migrans (EM) reacted with one to three 
variants of the recombinant OspC (rOspC) in the acute or convalescent phase, respectively. Of 
the patients, 53% with NB and 53% with LA had IgM antibodies to rOspC, whereas 33% with 
NB and 60% with LA had IgG antibodies to rOspC. Cross-reactivity existed in Epstein-Barr 
virus (EBV) infections in IgM ELISA, but this could be reduced by using thiocyanate in serum 
dilution buffer. In IgM serology the immunoreactivity was stronger against rOspC from B. 
afzelii and B. garinii than against rOspC from B. burgdorferi sensu stricto. Because of the 
heterogeneity of OspC, a polyvalent antigen with several OspC variants from at least B. afzelii 
and B. garinii is needed to improve the sensitivity of OspC ELISA in the serodiagnosis of LB 
in Europe.  
 
Three variant recombinant antigens of decorin-binding protein A (DbpA), BBK32, and OspC, 
and B. garinii type IR6 peptide were applied in the diagnosis of NB, using cerebrospinal fluid 
(CSF) and serum samples of 89 patients. Their performances in IgG ELISA were compared 
with that of a commercial flagella antigen. IgM ELISA was performed with rOspC and 
flagella. The new antigens confirmed the positive NB diagnoses aided by anti-flagella 
antibodies. More importantly, of those NB patients negative for anti-flagella antibodies in the 
CSF, 51% were positive for at least three new antigens and 68% for at least two new antigens 
(mainly DbpA and IR6) in the CSF. Antibodies to rDbpA and IR6 were observed in the CSF in 
early and late NB, while antibodies to rBBK32 were detected mainly early in the disease. New 
antigens performed well also in the serum analyses but the discriminatory power between 
patient and control samples was better in the CSF than in serum. Thus, the use of the new 
antigens at presentation of the disease seems to improve the accuracy of laboratory diagnosis of 
NB. In IgG ELISAs, the diagnostic sensitivity of assays with the new antigens was between 75 
and 88%, but with the flagella antigen was only 52%. The specificity of the tests varied 
between 92 and 98%. The results suggest that antibody positivity in the CSF to at least two 
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new antigens could be used as a confirmatory laboratory marker for NB. Furthermore, 
antibodies to BBK32 might be suggested as a marker of early LB.   
 
To find a serological marker of successful treatment of LB, consecutive serum samples from 
68 treated patients with late LB were analysed during a 1 to 2 year follow-up period 
posttreatment. End-point ELISA titres of IgG1, IgG2, IgG3, and combined IgG1+3 subclasses 
against a sonicate antigen of B. burgdorferi were determined and compared to the IgG antibody 
response against B. burgdorferi flagella. Individual half-lives of the antibody levels were 
calculated for each patient, and compared with the patients´ clinical outcome. The half-life of 
flagella antibodies was found to be significantly shorter than that of sonicate antigen after 
successful treatment of late LB. The decrease was observed mainly in the IgG1 and IgG4 
responses to flagella. The results suggest that a rapid decrease in flagella antibodies may be 
used as a marker of a successful treatment of LB. A decrease in titre to half that of the pre-
treatment level within 6 months suggests eradication of the disease. 
  
In conclusion, assessment of antibodies to the new recombinant and peptide antigens alone or 
in parallel seems to increase the accuracy of laboratory diagnosis of LB. Still, the sensitivity 
and specificity, especially in IgM serology with single recombinant antigens, remained 
suboptimal. In European conditions, if immunogenic borrelial proteins are used as antigens in 
the serology of LB, sequence heterogeneity between species implies that variant proteins are 
needed to cover all the relevant borrelial species. Further studies with new antigens are needed 
to find an antibody test that would differentiate between active and past infection early during 
the follow-up of patients treated for LB. 
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1 INTRODUCTION
 
Historical remarks. In 1975, the rheumatologist Allen C. Steere began to investigate patients 
with arthritis in Connecticut close to the town of Old Lyme. He and his co-workers observed 
that, in addition to arthritis, these patients also had clinical histories including erythema 
migrans (EM), neurological abnormalities and carditis (Steere 1977). A tick-transmitted 
infectious agent was suspected but not found until 1981, when the aetiological spirochaete of 
Lyme borreliosis (LB) was isolated by Dr. Willy Burgdorfer from Ixodes ticks collected on 
Long Island, New York (Burgdorfer et al. 1982). The isolate was subsequently identified as a 
new species of Borrelia and was named Borrelia burgdorferi in 1984 (Johnson 1984). The 
clinical manifestations of LB in humans had been known in Europe for more than 100 years. In 
1883 the German physician Alfred Buchwald described a “diffuse idiopathic skin atrophy”, 
now regarded as acrodermatitis chronica atrophicans (ACA). EM was first presented and 
named by the Swedish dermatologist Arvid Afzelius in 1909 (Afzelius 1910). Borrelial DNA 
isolated from archived ticks verifies the exposure to B. burgdorferi for more than a century 
(Matuschka et al. 1996).  
Clinical manifestations. Differences in the clinical symptoms of disseminated LB between 
patients in Europe and the United States were soon observed. In Europe, severe neurological 
manifestations were frequent, whereas, in the United States, arthritis, carditis and milder forms 
of encephalopathy prevailed. Recognition of different species of B. burgdorferi associated with 
different clinical patterns of LB (van Dam et al. 1993) and with different geographical areas 
has expanded our knowledge and understanding of borrelial infections during the last decade. 
LB is now considered to be the most common vector-borne disease in North America (Steere 
1994, Centers for Disease Control and Prevention (CDC) 1997) and in Eurasia (O´Connell et 
al. 1998).  
 
Conventional methods. New methods of diagnosing LB have been developed. Borreliae were 
at first identified by culturing, by dark-field microscopy and by indirect immunofluorescence 
assay (IFA). An enzyme-linked immunosorbent assay (ELISA) is nowadays the serological 
method most commonly used for diagnosing LB. Regrettably, there are problems with current 
routine assays. The antigens in use have suboptimal sensitivity, especially at the early stage of 
LB. This is true of serum as well as of cerebrospinal fluid (CSF). False-positive IgM reactions 
are caused by viral infections, rheumatoid arthritis, and other spirochaetal diseases such as 
syphilis or parodontitis. In a subgroup of patients, antibody levels both in serum and in CSF 
may stay high for prolonged periods even after successful treatment (Craft et al. 1984, Wilske 
et al. 1986, Kruger et al. 1989, Feder et al. 1992, Hammers-Berggren et al. 1993, 1994a and 
1994b, Lomholt et al. 2000, Kalish et al. 2001). Thus, there is no reliable laboratory marker to 
indicate an active LB or cure. Even a confirmatory Western blot (WB) analysis on ELISA 
positive samples (CDC 1995) or a polymerase chain reaction (PCR) (Schmidt 1997) have not 
resolved the problems.  
 
New methodology. Recently, recombinant antigens have been applied to improve the laboratory 
diagnosis of LB. Use of recombinantly produced borrelial antigens has increased the specificity 
of ELISA assays, but sensitivity with single antigens has so far remained insufficient. 
 
In this study, recombinant antigens of flagellin A (FlaA) and outer surface protein C (OspC) 
from three pathogenic species of B. burgdorferi were individually applied in serological 
methods. The amino acid sequences of these proteins in Finnish Borrelia strains were studied 
as well. The performance of three variants of recombinant decorin-binding protein A (rDbpA), 
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BBK32 (rBBK32) and OspC (rOspC) antigens, and of VlsE IR6 peptide was compared with a 
commercial flagella antigen in the laboratory diagnosis of neuroborreliosis (NB). Antibodies to 
flagella as a serological marker of disease activity was also studied.  
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2 REVIEW OF THE LITERATURE
2.1 GENERAL ASPECTS OF BORRELIA SPIROCHAETES
2.1.1 Genus Spirochaetales
Order Spirochaetales is divided into three major phylogenetic groupings, or families: 
Spirochaetaceae, Serpulinaceae and Leptospiraceae. Spirochaetaceae include species of the 
genera Borrelia, Brevinema, Cristispira, Spirochaeta, Spironema, and Treponema. The second 
family Serpulinaceae contains the genus Brachyspira (Serpulina). The third family, 
Leptospiraceae, contains species of the genera Leptonema and Leptospira. Borreliae include 
several Borrelia species that are associated with diseases of humans and animals. It is 
characteristic of Borreliae that all species are transmitted to vertebrates by haematophagous 
arthropods. Borrelia species causing disease in humans are B. hermsii, B. recurrentis and some 
other less frequent Borrelia species which cause relapsing fever, and B. burgdorferi sensu lato 
causing Lyme disease (Schwan et al. 1986, Paster and Dewhirst 2001). 
 
2.1.2 Borrelia burgdorferi sensu lato
 
Lyme disease is caused by B. burgdorferi sensu lato, including B. burgdorferi sensu stricto, B. 
afzelii, and B. garinii. Based on the genotypic methods (see below), seven additional Borrelia 
species have been identified within the B. burgdorferi sensu lato complex. A few cases of LB 
associated with B. valaisiana and B. bissettii have been reported (Picken et al. 1996, Rijpkema 
et al. 1997) but their role as causative agents of LB is still unclear. B. japonica, B. lusitaniae, 
B. andersonii, B. tanukii, and B. turdi belong to the sensu lato complex but they are not known 
to cause human infections (Wang et al. 1999). Isolates belonging to the B. burgdorferi sensu 
lato complex are categorised by either phenotypic or genotypic methods.   
 
Serotyping, the most commonly used phenotypic method, is based on the heterogeneity of the 
outer surface protein A (OspA) or OspC of B. burgdorferi sensu lato. This serotyping is 
performed using monoclonal antibodies. Eight different OspA serotypes have been described 
in Europe (Wilske et al. 1993b and 1996a), and among Japanese B. burgdorferi sensu lato 
isolates, OspA serotypes J1 to J11 from ticks only (Masuzawa et al. 1996, Yanagihara and 
Masuzawa 1997) (Fig 1). European OspA serotypes 1 and 2 correspond to B. burgdorferi sensu 
stricto and B. afzelii, respectively, and serotypes 3 to 8 correspond to B. garinii (Wilske et al. 
1996b). Japanese OspA serotypes J 1 to J 9 correspond to B. garinii, type J10 to the European 
B. afzelii strains of serotype 2, and type J11 to B. japonica (Yanagihara and Masuzawa 1997).  
 
Sixteen different OspC serotypes have been defined for the European and North American 
isolates (Wilske et al. 1995 and 1996b). OspC is much more heterogeneous than OspA, 
especially for the B. burgdorferi sensu stricto and B. afzelii strains. While only one OspA 
serotype is known for each of these species, six OspC serotypes for B. burgdorferi sensu stricto 
and four OspC serotypes for B. afzelii have been identified (Fig 1).  
 
Another example of phenotypic methods is multilocus enzyme electrophoresis. In this method, 
bacterial lysates are subjected to electrophoresis under nondenaturing conditions and the 
electrophoretic mobility of metabolic enzymes is determined after specific staining. Results can 
be directly correlated with the genotype (Wang et al. 1999). This method has been used to 
analyse the population genetics of B. burgdorferi sensu lato, and the isolates were grouped into 
three main divisions corresponding to B. burgdorferi sensu stricto, B. garinii, and B. afzelii 
12
(Boerlin et al. 1992). For Borreliae, this method is, however, labour-intensive, as large 
quantities of spirochaetes have to be grown to obtain enough lysates for analyses.  
            
           
           
           
           
        
 

Fig. 1. Relationship between species, and OspA and OspC serotypes of B. burgdorferi sensu lato. Modified from 
Wilske et al. 1996b and Wang et al. 1999. OspA serotype J10 corresponds to the European B. afzelii strains of 
serotype 2. The OspC types are divided into two columns for illustration, not indicating any pairwise relationship. 
OspC type OspA type Species 
B. burgdorferi 
sensu lato 
Type3 PBr
B. japonica Type J11 
B. garinii 
Type 4 PBi 
Type 5 WABSou
Type 6 TN N34 
Type 7 T25 
Type 8 
Type J1 to J9 
B. afzelii Type 2 PKo PLud 
PLe PLj7 
B. burgdorferi 
sensu stricto
Type 1 
B31 B.pac.
297 T255 
Pstm PBre 
  
 
13 
Genotypic methods, where molecular typing is based on the genetic characteristics of 
microorganisms, provide more precise information on the diversity of pathogenic bacteria. For 
Borreliae, the most commonly used methods are pulsed-field gel electrophoresis (PFGE), 
PCR-based restriction fragment length polymorphism analysis (PCR-RFLP), plasmid 
fingerprinting, or DNA sequence analysis (Wang et al. 1999). In PFGE the bacterial genomic 
DNA is separated after digestion with a restriction enzyme. This method has shown to be 
highly effective molecular typing technique for many bacterial species (Goering et al. 1995, 
Tenover et al. 1995). PCR-based RFLP analysis with species-specific primer, based on the 
unique rRNA structure of these microorganisms, have been applied to typing of B. burgdorferi 
directly in human tissue specimens and field-collected ticks (Liveris et al. 1996 and 1999). 
Since both the number and size of plasmids varies among strains, plasmid profile analysis may 
also be used for strain and species identification of B. burgdorferi sensu lato. In DNA sequence 
analysis, B. burgdorferi sensu lato can be classified on the basis of phylogenetic relationships, 
comparing either the entire genome sequences, the highly conserved gene loci or the bacterial 
16S rRNA of the organisms (Wang et al. 1999).  
 
2.1.3 Natural cycle of B. burgdorferi
 
Borreliae are maintained in nature by cycling through wild animals (mammalian hosts and 
birds) and the ticks that feed upon them. The principal tick vectors for Lyme disease are Ixodes 
ricinus in Europe, I. ricinus, I. dammini or rarely I. pacificus in the United States, and I. 
persulcatus in Asia. The larvae and nymphs feed primarily on small rodents, and adult ticks on 
a variety of mammalian species. The tick becomes infected while feeding on the blood of an 
infected mammal or bird (Sonenshine 1991). The mechanisms underlying the transmission of 
B. burgdorferi sensu lato by various mammalian and avian hosts remain to be determined, 
although differences in serum complement sensitivity among Borrelia species may be a key 
factor in LB ecology (Kurtenbach et al. 1998, Stevenson et al. 2002). According to differences 
in complement sensitivity, B. afzelii strains as well as B. garinii serotype 4 are resistant to 
normal human serum (NHS). B. garinii serotypes 3 and 5 to 8 are sensitive to NHS, and B. 
burgdorferi sensu stricto strains have intermediate complement-sensitivity (van Dam et al. 
1997, Kurtenbach 1998). Some species of ticks may rarely also pass spirochaetes on to the next 
generation via eggs (vertical or transovarian transmission) (Piesman et al. 1986, Lane and 
Burgdorfer 1987).  
 
In Ixodes ticks infected with B. burgdorferi, the spirochaetes are usually restricted to the 
midgut during periods when the ticks are off their hosts (Burgdorfer 1989). During tick 
engorgement, spirochaetes multiply and penetrate the midgut to invade the haemolymph and 
spread to the salivary glands, from which they may be transmitted to human via saliva that is 
secreted during the later stages of tick feeding (Piesman et al. 1987, Zung et al. 1989). The 
ability of B. burgdorferi to infect a host is determined by many factors including 
immunomodulatory tick salivary components (Sigal 1997b). Also, the risk of infection after a 
tick bite increases if the tick has been attached for more than 24 hours (Berger et al. 1995), and 
especially, if attached over 53 hours (Ohnishi et al. 2001). Nymphal ticks may transmit the 
infection more frequently than adult ticks (Matuschka et al. 1992). Possibly, nymphs remain 
undetected for longer periods, whereas the adult is large enough to be noticed and promptly 
removed.    
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2.1.4 Morphology and molecular structure of B. burgdorferi
Borreliae are highly motile helical gram-negative bacteria with 5 to 25 µm length and with 0.2 
to 0.5 µm width. An outer membrane surrounds the periplasmic space containing the 
subterminal flagella (7 to 20 per terminus), which are attached to a protoplasmic cylinder. The 
outer membrane is comprised of 46% protein, 51% lipid and 3% carbohydrate. Outer 
membrane lipoproteins of B. burgdorferi (OspA to OspF) have been antigenically studied but, 
for diagnostic purposes, only OspC has had importance. Flagella mediate both the motility and 
the spiral shape of Borreliae. Movement of the bacteria depends on rotation of the flagella. 
When Borrelia moves forward, the flagella at the opposite ends rotate in the opposite direction 
(translation-type movement). If the flagella at the opposite ends rotate in the same direction, 
Borrelia flexes, bends, and makes a turn (non-translation-type movement) (Goldstein et al. 
1994, Li et al. 2002). Each flagellum consists of a basal disk, neck, hook, and filament portion. 
Flagella have an outer sheath protein, flagellin A, and a core protein, flagellin B. The 
protoplasmic cylinder, the innermost compartment of B. burgdorferi, contains ground 
substance, nucleoplasm, ribosomes and mesosomal components (Barbour and Hayes 1986, 
Hayes and Burgdorfer 1993). Fig. 2 shows the structure of B. burgdorferi. 
Fig. 2. Longitudinal and cross-sectional views of the structure of Borrelia. Modified from figure provided on the 
internet (Johnsson 2002). 
2.1.5 Molecular biology of B. burgdorferi
The whole genome of B. burgdorferi has been cloned and sequenced except for parts of 
homologous plasmids (Fraser et al. 1997). The unique structure of the genome of B. 
burgdorferi contains a linear chromosome of 910,725 bp, and up to 21 plasmids (9 circular and 
12 linear). The low guanine-plus-cytosine  (G+C) content of 29% in the chromosome and of 23 
to 32% in individual plasmids is characteristic of borrelial DNA (Simpson et al. 1990, Casjens 
and Huang 1993, Casjens et al. 1997). In other gram-negative bacteria, e.g. Enterobacteriaceae 
(Escherichia coli), the G+C content is 39 to 59% (Farmer 1999). The circular plasmid cp26 in 
the B. burgdorferi B31 strain contains a resT gene that is essential for multiplication of the 
linear plasmids and the chromosome. Therefore, cp26 could be designated as a 
minichromosome (Kobryn and Chaconas 2002). A correlation between linear plasmids lp25 
and lp28-1 and the infectivity of B. burgdorferi B31 has been shown in mice. Spontaneous loss 
of lp25 during in vitro culture results in loss of infectivity, whereas absence of lp28-1 results in 
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an intermediate infectivity phenotype (Xu et al. 1996, Purser and Norris 2000, Labandeira-Rey 
and Skare 2001). It has been determined that the gene pncA (BBE22), encoding a putative 
nicotinamidase, is able to restore infectivity to lp25 minus organisms (Purser and Norris 2000). 
 
Borrelia isolates showing less than 70% homology with each other in genotypic methods are 
suggested to belong to different genospecies (Baranton et al. 1992, Dykhuizen et al. 1993, Le 
Fleche et al. 1997). Both the number and size of the plasmids can vary among srains. Plasmid 
loss occurring during in vitro cultivation (Schwan et al. 1988) may result in a DNA-DNA 
relatedness below 100% between an isolate and its subcultured variants or among closely 
related strains. The chromosomes are more uniform in structure than the plasmids of B. 
burgdorferi. The one exception to this uniformity is length variation of about 20 kbp at the 
extreme right terminus of the chromosome (Casjens 2001). B. garinii shows the greatest 
genetic heterogeneity (Foretz et al. 1997).  
 
Approximately 150 lipoprotein genes have been described in B. burgdorferi (Casjens et al. 
2000). Of these lipoproteins, 19 have recognised counterparts in other bacteria (Liang et al. 
2002b). A lipoprotein-encoding family of seven genes designated 2.9 LP, recently renamed 
mlp, has been found on circular and linear plasmids (Porcella et al. 1996, Yang et al. 1999). 
mlp genes are prefentially expressed at a temperature of 35°C, suggesting that expression 
occurs after transmission in vivo. Serum antibodies reactive with purified recombinant Mlp 
proteins have been shown in patients with LB. mlp genes encode a diverse array of outer 
surface lipoproteins which may participate in early infection processes in the mammalian host 
and may participate in host-pathogen interactions (Akins et al. 1998, Porcella et al. 2000). 
OspE and OspF homologues represent a closely related family of lipoproteins encoded on 
plasmids homologous with cp32 and cp18. The strain 297, N40, and B31 lipopoteins comprise 
three evolutionarily distinct families (OspE, OspF and OspE/OspF-like leader peptides) with 
highly conserved N-terminal leader peptides (Marconi et al. 1996, Stevenson et al. 1996, 
Casjens et al. 1997, Akins et al. 1999). Distinct expression profiles for these proteins have been 
shown, depending on the conditions of the spirochaete (in-vitro cultivation, location in the 
midgut of a tick or in a mammalian host) (Hefty et al. 2001), and thus, these molecules may 
have relevance for the pathogenic events of early LB.  
 
2.1.6 Molecules studied in this thesis in the biology of B. burgdorferi
 
The borrelial flagellum (plural flagella) is the polymerised functional structure of flagellin 
proteins A (FlaA) and B (FlaB). The flagellum consists mainly of FlaB with a minor amount of 
FlaA. Intact isolated flagella are used as antigens in one commercial ELISA test (Dako, 
Denmark). Recombinant flagellin fragments such as the 14-kDa flagellin fragment also 
mentioned elsewhere in this study are derived from FlaB. 
 
The flagellar core protein FlaB of 41 kDa molecular mass polymerises to form the major 
periplasmic flagellar filament. It participates in skeletal function, since flaB mutant Borreliae 
lacking the gene encoding FlaB are nonmotile and rod-shaped (Motaleb et al. 2000). 
Antibodies to FlaB do not appear to harm the bacteria. Therefore, in living Borrelia, the 
flagella appear to be shielded by the outer membrane.  
 
FlaA is a 37 kDa outer sheath protein of the flagellum. A flagellum/chemotaxis operon 
(fla/che) upstream of the putative cheA gene is part of the motility-chemotaxis operon (Ge and 
Charon 1997, Revel et al. 2002). FlaA contains a signal sequence at its N terminus including a 
positively charged N-terminal domain, a central hydrophobic segment, and a signal peptidase I 
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cleavage site. The amount of B. burgdorferi FlaA has been suggested to be only approximately 
10% of the amount of FlaB (Ge et al. 1998). Therefore, FlaA may not cover FlaB completely. 
The function of FlaA in Borrelia is unknown. 
 
OspC is a temperature and pH regulated 21-22 kDa outer surface lipoprotein of B. burgdorferi 
(Schwan et al. 1995, Stevenson et al. 1995). It is upregulated during nymphal feeding and 
when the spirochaetes transfer from tick to human (Schwan and Piesman 2000). Early in the 
infection of mammals there is an antibody response towards OspC, which limits the expression 
of OspC and slows down the multiplication of Borrelia. Despite OspC antibodies, Borrelia is 
able to survive in the mammalian host (Liang et al. 2002a). Borreliae may use extensive 
variation of OspC to avoid mammalian antibodies (Jauris-Heipke et al. 1995, Livey et al. 
1995). 
 
DbpA is an 18-20 kDa outer surface protein capable of binding mammalian connective tissue 
decorin. It is produced by Borreliae in vitro and in vivo, and is also temperature-regulated. 
DbpA elicits a strong antibody response during experimental murine borreliosis (Cassat et al. 
1998, Feng et al. 1998, Hagman et al. 1998) and has been suggested as a potential vaccine 
candidate (Hanson et al. 1998). Membrane lipoproteins DbpA and OspC are regulated via a 
novel pathway that involves the alternate sigma factors RpoN and RpoS (typically associated 
with general stress responses in bacteria) (Hubner et al. 2001).   
 
BBK32 is a 47 kDa fibronectin-binding protein expressed by the spirochaetes preferentially in 
vivo. It is detectable in spirochaetes during tick feeding even before transmission to the host 
but not in unfed ticks. Thus, BBK32 is up-regulated during the transmission to mammalian 
tissue but decreases thereafter to low levels (Probert and Johnson 1998, Fikrig et al. 2000, 
Revel et al. 2002). Antibodies to BBK32 have been observed in mice (Akin et al. 1999) and in 
humans (Fikrig et al. 1997, Heikkilä 2002b), but their role in combating Borrelia is unclear.  
 
The invariable region (IR)6 is a peptide of surface-exposed antigenic variation lipoprotein of B. 
burgdorferi (VlsE). This variable major protein (vmp)-like sequence (vls) in B. burgdorferi 
closely resembles the vmp system of B. hermsii. The vls expression site (vlsE) and 15 
additional silent vls cassettes have been identified on a 28 kb linear plasmid. IRs including IR6 
are conserved among strains and genospecies of B. burgdorferi sensu lato (Zhang et al. 1997). 
IR6 is the most conserved of the IRs and it has been shown to be immunodominant both in 
monkeys and in humans infected with B. burgdorferi (Liang 1999a). A curious observation is 
that antibodies to IR6 do not harm Borrelia even though antibodies to other epitopes of VlsE 
are restrictive to the growth of Borrelia (McDowell et al. 2002). 
 
 
2.2 CLINICAL MANIFESTATIONS OF LYME BORRELIOSIS
 
2.2.1 Classification of Lyme borreliosis
 
LB has been divided into three stages (according to the duration of the disease): I early 
localised, II early disseminated and III late disseminated borreliosis (Åsbrink 1991). The stages 
are not always clear-cut and various symptoms and signs may overlap. The major sign in stage 
I is EM. Secondary multiple EM as well as neurological manifestations, arthritis, carditis or 
myalgia may be signs in stage II. Stage III includes chronic organ involvements of LB 
manifested as encephalomyelitis, peripheral neuropathy, ACA, and chronic arthritis with a 
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history of symptoms for more than 6 or 12 months (Nadelman and Wormser 1998, Wang et al. 
1999, Steere 2001) (Table 1). 
 
 
 
Table 1. Major clinical manifestations of  
Lyme borreliosis by stage. 
_____________________________________ 
Stage Manifestation 
_____________________________________ 
Early 
 Localized Erythema migrans   
  (stage I) Regional adenopathy 
   Mild systemic symptoms 
_____________________________________ 
 Disseminated Radiculoneuritis 
  (stage II) Cranial neuritis 
   Meningitis 
   Multiple erythema migrans 
   Lymphocytoma 
   Arthritis/Arthralgia 
   Myalgia 
   Carditis 
   Myeloencephalopathy 
_____________________________________ 
Late (stage III) Encephalomyelitis 
   Peripheral neuropathy 
   Acrodermatitis 
     chronica atrophicans 
   Chronic arthritis 
_____________________________________  
2.2.2 Cutaneous manifestations
Erythema migrans. EM appears in the early stage of LB one to three weeks after the tick-bite. 
The skin rash typically spreads centrifugally and may be either homogeneous or ring-shaped or 
vesicular. All three species of B. burgdorferi can cause EM and no significant difference 
between the occurrence of EM and infection with a particular Borrelia species has been 
reported. However, EM patients with B. burgdorferi sensu stricto in North America seem to 
suffer more frequently from systemic symptoms than EM patients in Europe (Nadelman et al. 
1996, Strle et al. 1996 and 1999), where EM is caused predominantly by B. afzelii (van Dam et 
al. 1993, Saint Girons et al. 1998) and to a lesser degree by B. garinii. Occasionally, more than 
a single species of B. burgdorferi sensu lato has been shown to be present in an EM lesion 
(Wienecke et al. 1994, Seinost et al. 1999). van Dam et al. 1993 have proposed that EM caused 
by B. afzelii may last longer than EM with B. garinii. Multiple EM lesions related to 
haematogenous dissemination are also seen more frequently in North America (50%) than in 
Europe (4-8%) (Wormser et al. 1999). In approximately 70% of EM patients, the skin rash is 
accompanied by low-grade fever, headache, fatigue, arthralgia and myalgia (Weber and 
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Neubert 1986, Nadelman et al. 1996). Of note, respiratory or gastrointestinal symptoms are not 
typical manifestations of LB. EM was noticed in 34 to 64% of NB patients in Europe 
(Stiernstedt et al. 1988). In 30 to 50% of cases, EM is preceded by a recognized tick-bite and 
rarely by a sting of a flying insect (Weber et al. 1983, Åsbrink and Hovmark 1988, Oksi et al. 
1994a).  
 
Lymphocytoma. A borrelial lymphocytoma is a rare tumour-like bluish-red infiltrate often 
located on the breast nipple, the ear lobe or the scrotum (Åsbrink and Hovmark 1988). The 
time from the tick bite to the appearance of the lymphocytoma ranges between 1 and 6 months. 
EM often precedes a lymphocytoma but these may also appear simultaneously. A 
lymphocytoma usually appears after systemic infection with B. burgdorferi and as part of stage 
II of the disease (Pohl-Koppe et al. 1998). It can also sometimes be present as multiple lesions, 
and in rare cases it has been shown to be associated with a B cell lymphoma (Garbe et al. 
1991). A lymphocytoma is usually caused by B. afzelii and is, thus, reported in connection with 
LB only in Europe (Hovmark et al. 1993). However, Picken et al. (1997) have shown one 
lymphocytoma case with another distinct genomic group of B. burgdorferi sensu lato (DN 127-
group) and Busch et al. (1996b) reported two lymphocytoma patients with B. garinii as the 
causative agent. Untreated lymphocytoma resolves spontaneously, but it may last for up to 1 
year (Hovmark et al. 1993).  
 
Acrodermatitis chronica atrophicans. ACA is a late cutaneous manifestation of LB 
characterised by chronic and long-lasting progressive red and bluish-red skin atrophy usually 
on the extensor surfaces of the extremities. The disease may occur from 6 months to 8 years 
after the initial infection (Leslie et al. 1994). It may be accompanied by local swelling, fibrous 
nodules or sclerotic bands over the affected joints, subluxations or an exaggerated pain reaction 
called allodynia (Brehmer-Andersson et al. 1998). Occasional cases with ACA located on the 
face have been published but only one confirmed with positive PCR (Muller et al. 1994). ACA 
is usually seen in adults, but a few cases in children have also been published (Muellegger et 
al. 1996, Brzonova et al. 2002). ACA is predominantly caused by B. afzelii, but some cases 
with B. garinii or B. burgdorferi sensu stricto as a causative agent have been reported in 
Europe (Picken et al. 1998) and in the United States (Mathiesen et al. 1997).  
 
2.2.3 Neuroborreliosis
 
If LB disseminates, neurological manifestations may follow. Neurological abnormalities of any 
kind have been reported to occur in 15 to 20% of all untreated LB patients (Weber and Neubert 
1986). Musculoskeletal symptoms and headache without objective neurological signs have 
been reported even more frequently at all stages of the infection (Steere et al. 1983a). In 
Europe, NB is more common than in the United States (Ciesielski et al. 1989, Christen et al. 
1993, Kaiser 1994, Garcia-Monco and Benach 1995, Halperin et al. 1996).  
 
Early NB. Manifestations of early NB include meningitis, cranial and peripheral nerve 
neuropathies, and Bannwarth´s syndrome (lymphocytic meningoradiculitis) (Kaiser 1998, 
Oschmann et al. 1998). In Europe, meningeal symptoms in LB patients with meningitis are 
often mild or absent (Garcia-Monco 1993). Cranial neuropathies develop in 47 to 82% of NB 
patients (Pfister et al. 1993), and 70 to 80% of these have facial palsy (FP) (Reik 1991).  
 
Late NB. Chronic NB is rare and includes forms of encephalitis, encephalomyelitis, 
meningoencephalitis and radiculitis (Kristoferitsch 1991, Hansen and Lebech 1992). In Europe, 
meningoradiculitis has been the most frequent initial neurological manifestation (Backenson et 
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al. 1995), whereas in American patients, peripheral neurological signs such as 
mono/polyneuritis as well as conditions with mild non-focal alterations of cognitive function 
and memory have often been reported (Halperin 1998).  
 
All three species, B. burgdorferi sensu stricto, B. garinii, and B. afzelii, are known to cause 
NB. In Europe, B. garinii has been isolated in 58 to 72% of the CSF samples of NB patients, 
whereas in 8 to 11% and in 20 to 28% of the specimens B. burgdorferi sensu stricto and B. 
afzelii, respectively, have been the causative agents (Busch et al. 1996a, Hubalek and Halouzka 
1997). Other studies have also suggested an association between B. garinii infection and the 
development of NB (Balmelli and Piffaretti 1995, Wilske et al. 1996a, Peter et al. 1997). 
Furthermore, a few cases with mixed infection of B. afzelii and B. garinii have been seen 
(Stunzner et al. 1999). 
 
2.2.4 Musculoskeletal manifestations
 
Arthritis appears late after the onset of illness. Brief intermittent attacks of joint swelling and 
pain, primarily in the large joints, especially the knee, are typical of Lyme arthritis (LA). 
Episodes of either migratory monoarthritis or asymmetric oligoarthritis occur, lasting a mean 
of three months (Steere et al. 1987, Steere 1989). In Europe, where B. afzelii and B. garinii are 
more frequently responsible for LB than B. burgdorferi sensu stricto, only 3 to 15% of patients 
suffer from arthritis (Berglund et al. 1995, Cimmino et al. 1998). In North America, about 60% 
of patients with untreated early LB get LA (Steere 1989). 
 
Other musculoskeletal manifestations associated with LB include myositis (Schmutzhard et al. 
1986, Reimers et al. 1993) and in a few cases osteomyelitis (Jacobs et al. 1986, Oksi et al. 
1994b). Arthralgia and myalgia are frequently seen in patients with early LB in North America 
but only in every fifth patient in Europe (Steere et al. 1983a, Weber and Neubert 1986). 
Occasionally, LB has been proposed to elicit fibromyalgia (Dinerman and Steere 1992). 
 
2.2.5 Cardiac manifestations
 
Lyme carditis, usually appearing several weeks after the onset of the disease, is a well-known 
clinical manifestation in both North American and European patients with LB (Steere et al. 
1980, van der Linde 1991). The frequency of Lyme carditis has been shown to be higher in 
North America, where 0.5 to 10% of untreated LB patients present with cardiac abnormalities 
(Ciesielski et al. 1989, Steere 1989, Gerber et al. 1996). In Europe, the frequency of cardiac 
abnormalities among patients with LB is 0.3 to 2% (Berglund et al. 1995, Cimmino 1998, 
Huppertz et al. 1999). The most common clinical signs are fluctuating degrees of 
atrioventricular block, occasionally acute myopericarditis or mild left ventricular dysfunction, 
and rarely cardiomegaly or fatal pancarditis (Steere 1989). In Europe, B. burgdorferi has been 
isolated from endomyocardial biopsy samples of several patients with chronic dilated 
cardiomyopathy (Stanek et al. 1990, Lardieri et al. 1993).  
 
2.2.6 Ocular borreliosis
 
Ocular manifestations of LB include neuro-ophthalmic disorders, external ocular 
inflammations, and intraocular inflammations. Neuro-ophthalmic manifestations are various 
and may include, for example, cranial neuropathies, optic nerve disease, papilledema, uveitis, 
keratitis, neuroretinitis, destruction of retinal pigment epithelium, retinal vascular 
involvements, chorioiditis, vitritis, and conjunctivitis (Lesser 1995, Karma et al. 1996, Balcer 
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et al. 1997, Mikkilä et al. 1997a and 1997b, Zaidman 1997). Ophthalmic manifestations are 
rare but have been reported in all stages of LB: conjunctivitis in early localized stage, neuro-
ophthalmic manifestations in the early disseminated stage, and episcleritis and keratitis in the 
late stage of LB. It is recommended to screen for antibodies to B. burgdorferi in cases of 
posterior segment inflammation of unknown aetiology and of patients with uveitis, especially 
when other symptoms and signs compatible with LB are present (Mikkilä 1998).  
 
2.2.7 Other manifestations
 
Subclinical hepatitis with elevated serum transaminases (Kazakoff et al. 1993) and 
splenomegaly (Cimmino et al. 1989, Nelson and Nemcek 1992) as well as microscopic 
haematuria, and proteinuria (Steere 1989) have been noted in case reports with LB. The 
incidence of manifestations of LB in Europe and in the United States are shown in Table 2. 
Table 2. Proportions of patients (%) with different manifestations of LB in Europe and in the 
USA. 
Reference EM NB LA BL ACA CARD OPHT 
 
Europe: 
       
Berglund et al. 1995 77% 16% 7% 3% 3% 0.5%  
Cimmino 1998 59% 34% 15%   2%  
Huppertz et al. 1999 89% 3% 5% 2% 1% 0.3%  
 
USA: 
       
Steere 1989 80% 15% 60%   5%  
Gerber et al. 1996 89% 5% 6%   0.5%  
Ciesielski et al. 1989 91% 18% 57%   10%  
Nadelman et al. 1998       <5% 
Abbreviations are: EM = erythema migrans, NB = neuroborreliosis, LA = Lyme arthritis, BL = borrelial 
lymphocytoma, ACA = acrodermatitis chronica atrophicans, CARD = carditis and OPHT = ophthalmological 
symptoms 
2.3 PATHOGENESIS OF LYME BORRELIOSIS
2.3.1 General aspects
After inoculation into the skin, B. burgdorferi migrates through the extracellular matrix and 
binds to its components, including proteoglycans (Isaacs 1994) and collagen. Borreliae are 
capable of destroying tissues directly or by immunological reactions (Kaiser 1998). 
Spirochaetal lipoproteins, which bind the CD14 molecule or toll-like receptor 2 on 
macrophages, are potent activators of the innate immune response, leading to production of 
several cytokines (Hirschfeld et al. 1999, Porcella & Schwan 2001). Despite the innate and 
adaptive immune reponses, B. burgdorferi may survive in certain sites. B. burgdorferi has been 
found inside endothelial cells, fibroblasts, synovial cells and macrophages (Ma et al. 1991, 
Klempner et al. 1993, Montgomery et al. 1993, Girschick et al. 1996). Specific binding of B. 
burgdorferi sensu stricto OspE to complement factor H may help the pathogen to evade 
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complement attack and phagocytosis (Hellwage et al. 2001). Several members of the OspE 
lipoprotein family may be involved in avoidance of the complement of the various mammalian 
host species (Alitalo et al. 2001, Stevenson et al. 2002). 
 
2.3.2 Dissemination/host counterattack
 
Type 1 helper T (Th1) cells, which are part of the adaptive immune response, are prominently 
activated during early experimental murine borreliosis (Kang et al. 1997). In humans, 
infiltrates of macrophages and T cells in EM lesions express messenger RNA for both 
inflammatory and anti-inflammatory cytokines (Table 3) (Muellegger et al. 2000). To spread in 
the skin, to reach the brain and other tissue matrices, Borreliae have to bind to and pass 
through the endothelium and also the blood brain barrier (BBB) (Garcia-Monco et al. 1990). 
The dissemination of Borreliae is facilitated by binding of human plasminogen and its 
activators to the surface of the spirochaete (Coleman et al. 1997), which leads to the activation 
of plasminogen to proteolytic plasmin. This may help the organism to move from the 
circulation to the tissue matrices. During the homing to specific sites, the organism attaches to 
certain host integrins (Coburn et al. 1993 and 1998), matrix glycosaminoglycans (Guo et al. 
1998), and extracellular-matrix proteins (Probert et al. 1998). As an example, decorin-binding 
proteins A and B of Borrelia bind decorin, a glycosaminoglycan on collagen fibrils, which may 
explain why the organism is commonly aligned with collagen fibrils in the extracellular matrix 
in the heart, nervous system and joints (Guo et al. 1998). A fibronectin-binding protein has also 
been described (Probert et al. 1998). 
2.3.3 Pathogenesis of clinical manifestations 
 
Cutaneous manifestations. In EM, it is thought that the expanding erythema and inflammatory 
cells in the skin are due to the migration of B. burgdorferi centrifugally from the inoculation 
site and binding to the components of the extracellular matrix (Sigal 1997). ACA is developed 
on sun-exposed acral surfaces, and the organism has been cultured from such skin lesions as 
long as 10 years after the onset of the disease (Åsbrink and Hovmark 1985). A decrease in the 
expression of the major histocompatibility complex (MHC) markers on Langerhans cells in the 
skin of patients with active ACA has been suggested (Silberer et al. 1995). In one study, the 
infiltrates of T cells and macrophages in these lesions had a restricted cytokine profile, with 
little or no production of interferon-γ (IFN-γ) but expression of tumour necrosis factor (TNF)-α 
and interleukin (IL)-4 (Muellegger et al. 2000). Ultraviolet B (UVB) irradiation of C3H mice 
infected with B. burgdorferi decreased the Th1 response (Brown et al. 1995), which may also 
decrease production of IFN-γ, as it is a Th1-induced cytokine. Thus, UVB may have effects on 
the immunopathogenesis of ACA. Table 3 shows known mechanisms in pathogenesis of 
clinical manifestations of LB. 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Suggested mechanisms in pathogenesis of different clinical manifestations of LB. 
Time Clinical 
manifestation 
Mechanism Cells Receptors Humoral and toxic mediators References 
1-3 wk EM Microbe binding to 
 
 
Innate immunity 
Connective tissue cells 
 
 
Macrophages, (T cells) 
Epitopes of 
D, GAG, FN  
 
Cytokine 
reseptors 
_ 
 
 
IFN-γ, TNF-α, IL-1β, IL-6, IL-10 
Guo et al. 1995, Kopp et 
al. 1995, Leong et al. 
1995, Guner 1996 
 
Muellegger et al. 2000 
1-6 mo NB 
 
Microbe binding to 
 
 
 
 
Cell damage 
 
 
Cell damage 
 
 
Cell damage 
 
Autoimmunity 
Astrocytes, oligo- 
dendrocytes,  
Schwann cells 
 
 
Neural cells 
 
 
Neuronal and oligo-
dendroglia cells 
 
Neural cells 
 
Axon proteins, gan-
gliocides, neuron and 
myelin components 
 
 
Galactosyl-
ceramide 
 
Cytokine 
reseptors 
 
Not 
applicable 
 
Not known 
 
Not known 
_ 
 
 
 
 
IL-1, TNF- α,  IL-6, IFN-γ, 
neopterin 
 
Nitric oxide (produced by 
microglias) 
 
Immune complexes 
 
Autoantibodies 
Garcia-Monco et al. 1989 
and 1990, Garcia-Monco 
and Benach 1997 
 
Dotevall et al. 1990, 
Weller et al. 1991, Nilsson 
et al. 1994, Porcella and 
Schwan 2001 
 
Tatro et al. 1994 
 
 
Coyle et al. 1990 
 
Garcia-Monco et al. 1988, 
Fikrig et al. 1993, Kaiser 
1995 
6 mo-2 
yrs 
LA Autoimmunity or cell 
damage 
T cells hLFA-1α Molecular mimicry to OspA, T- 
cell cytokines  
Sigal 1997a, Gross et al. 
1998 
6 mo-8 
yrs 
ACA Innate immunity Macrophages, (T cells) Cytokine 
reseptors 
TNF-α, IL-4 Muellegger et al. 2000 
 Connective 
tissue infection 
Innate immunity Macrophages CD14, TLR2 TNF, IL-1, IL-6, IL-10, IL-12 Hirschfeld et al. 1999, 
Porcella and Schwan 2001 
EM= erythema migrans, NB= neuroborreliosis, LA= Lyme arthritis, ACA= acrodermatitis chronica atrophicans, D= decorin, GAG= glycosaminoglycans, FN= fibronectin 
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Neuroborreliosis. B. burgdorferi can bind to several neural cells. The attachment to myelin-
rich Schwann cells has been reported to be partially mediated by galactosylceramide, a 
glycolipid that has been found to serve as a receptor for other organisms, e.g. human 
immunodeficiency virus (HIV) (Garcia-Monco and Benach 1997). Encephalitis and radiculitis 
are probably due to direct destruction of the tissues. B. burgdorferi may even adhere and 
induce toxicity in neurons (Thomas et al. 1994). The sometimes late onset of FP (within two 
weeks after the start of treatment) indicates that other secondary mechanisms of nerve injury 
exist than destruction of neural cells caused by cytokines. B. burgdorferi-reactive T cells 
secreting IFN-γ have been reported in the CSF of NB patients (Forsberg et al. 1995, Wang et 
al. 1995), and especially in response to B. garinii outer surface proteins (Ekerfelt et al. 1998). 
Local inflammation also causes inflammation of small vessels (Oksi 1996), and this may 
further lead to destructive changes in the central nervous system (Wokke et al. 1987). The 
vasculopathic changes found in the brain in NB resemble endarteritis obliterans, a lesion earlier 
described in syphilis infections (Sigal 1997).  
Lyme arthritis. In about 10 per cent of patients, particularly those with certain HLA-DR alleles, 
the arthritis may persist in the knees for months or even for several years despite antibiotic 
treatment (Steere et al. 1994, Steere and Baxter-Lowe 1998). PCR for B. burgdorferi DNA in 
the synovium or joint fluid is almost always negative after treatment (Nocton et al. 1994, 
Carlson et al. 1999). Treatment-resistant and treatment-responsive arthritis seem to differ in the 
cellular and humoral immune responses to OspA (Kalish et al. 1993, Chen et al. 1999). It is 
assumed that, in some of the patients with treatment-resistant chronic arthritis, autoimmune 
mechanisms may play a role in the pathogenesis of the disease. Molecular mimicry between an 
immunodominant T-cell epitope of OspA of B. burgdorferi and human-lymphocyte-function-
associated antigen 1 (hLFA-1α), an adhesion molecule that is highly expressed on T cells in 
the synovium, is suggested as one plausible mechanism for the chronic arthritis (Gross et al. 
1998). 
2.3.4 Post-Lyme syndrome
In a subgroup of LB patients, continuing chronic symptoms are described, despite treatment 
with antibiotics. This so-called post-Lyme syndrome is suggested to be associated with 
immune-mediated mechanisms due to molecular mimicry leading to tissue destruction (Sigal 
1997a) or autoimmunity. Another suggestion has been slow recovery from the treatment. B. 
burgdorferi-induced autoantibodies towards neuronal components may be associated with 
pathogenesis of the chronic forms of NB. 
2.4 EPIDEMIOLOGY OF LYME BORRELIOSIS
The causative agent of LB in the United States is B. burgdorferi sensu stricto whereas in 
Europe all three species, B. burgdorferi sensu stricto, B. afzelii and B. garinii, can cause the 
disease. Human cases of LB occur predominantly in the northern hemisphere. LB is distributed 
over the northeastern, midwestern, and western regions of the United States as well as Canada 
and northern Asia (Schmid 1985, Nadelman and Wormser 1998). In Europe, LB is widely 
established in forested areas. The highest reported frequencies of the disease are found in 
central Europe and Scandinavia (Stanek et al. 1993). Despite reports of LB-like illnesses in 
Australia, Africa, South America, and the southern parts of the United States, B. burgdorferi 
has not been isolated from patients there. LB occurs with similar frequencies in males and 
females, and affects people of all ages.  
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In Finland, in the Turku archipelago the incidence of EM is reported to be 144/100 000 (Oksi 
1999). In southern Sweden, a prospective surveillance study reported the annual incidence of 
all manifestations of LB to vary between 26-160/100 000, depending on the location (Berglund 
et al. 1995). In a Danish study, the incidence of NB was 0.57-2.4/100 000 per year (Hansen 
and Lebech 1992). The annual incidence of NB in children aged 1 to 13 years was 5.8/100 000 
in Germany in an area endemic for LB (Christen et al. 1993). Huppertz et al. (1999) showed an 
incidence of all manifestations of LB to be 111/100 000. About 18 000 LB cases are reported 
each year in the United States (Orlowski et al. 2000). 
 
 
2.5 LABORATORY DIAGNOSIS OF LYME BORRELIOSIS
 
2.5.1 Culture
 
Culture of B. burgdorferi is the gold standard for diagnostic evidence of Lyme disease. B. 
burgdorferi grows in Barbour-Stoenner-Kelly (BSK) medium from biopsy samples of EM 
(Preac-Mursic et al. 1991), but it is difficult to obtain isolates from other clinical specimens. 
Cultures incubated at 33°C become positive within 2 to 3 weeks, occasionally earlier. Culture 
may be of help in individual cases if the clinical picture suggests LB despite a negative 
antibody assay, e.g. in atypical EM, in suspected NB without detection of intrathecal antibodies 
or in the cases of suspected LB in patients with immune deficiencies. Culture success rates of 
29% with saline-lavage needle aspiration (Wormser et al. 1992) and of 60% to 80% with punch 
biopsies of the advancing edges of EM lesions are reported (Berger et al. 1992, Wormser et al. 
1992). B. burgdorferi has been recovered by culture from a few specimens of patient blood 
(Benach et al. 1983, Nadelman et al. 1990, Wormser et al. 2000), CSF (Steere et al. 1983b), 
and joint fluid (Snydman et al. 1986). As the pathogen is only rarely detectable by culture, 
PCR often accompanies culture or is preferred to culture.  
 
2.5.2 Microscopy
 
Borreliae can be visualized in the light microscope, either by means of darkfield microscopy or 
by the use of special staining methods (Giemsa-, Fuchsin- or silverstaining) (Preac-Mursic and 
Wilske 1992). Because the number of organisms is too low for direct demonstration from 
patient specimens, microscopic detection (preferably by darkfield microscopy) is applied to 
monitor the growth of Borreliae in incubated cultures. However, microscopy is time-
consuming, lacks specificity and sensitivity and is not suitable for the routine diagnosis of LB 
(Wilske et al. 2000).  
 
2.5.3 Polymerase chain reaction (PCR)
 
Indications for PCR demonstration of the borrelial genomic DNA include cases with negative 
or borderline serological results, and cases with clinically equivocal LA or ambiguous 
dermatological or neurological manifestations. PCR is sensitive in detecting DNA from tissues 
but there is a risk of false-positive results (Schmidt 1997). PCR cannot be used to assess the 
effectiveness of antibiotic treatment, although a correlation of PCR results with clinical 
improvement has been shown (Kruger and Pulz 1991, Bradley et al. 1994, Halperin et al. 1994, 
Nocton et al. 1994, von Stedingk et al. 1995, Aberer et al. 1996).  
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Skin. The sensitivity of PCR in skin biopsy specimens from patients with EM is high, varying 
between 60 and 90% (Schwartz et al. 1992, Ranki et al. 1994, von Stedingk et al. 1995). It is 
necessary to have skin biopsy from the edge of the area of EM, since samples from the centre 
of the lesion may be negative (Schwartz et al. 1992). PCR of the vesicle fluid of vesicular EM 
has given positive results (Goldberg et al. 1992). Single studies with a positive PCR finding in 
patients with lymphocytoma have been published (Wienecke et al. 1993, Ranki et al. 1994). 
The PCR sensitivity of skin specimens in ACA is comparable to that in EM patients (Melchers 
et al. 1991, Moter et al. 1994). In skin specimens taken at the site of a previous erythematous 
lesion B. burgdorferi DNA may still be detected 1 to 6 months (in one patient, 45 months) after 
disappearance of the lesion (Kuiper et al. 1994, Strle et al. 1995). In rare cases, positive PCR 
findings have also been reported in some other dermatological manifestations, such as morphea 
(Aberer et al. 1991, Schempp et al. 1993, Trevisan et al.  1996), granuloma annulare (Strle et al. 
1991), lichen sclerosus et atrophicus (Schempp et al. 1993, Trevisan et al. 1994), in 
dermatomyositis (Fraser et al. 1992, Horowitz et al. 1994, Hoffman et al. 1995), and in 
eosinophilic fasciitis (Granter et al. 1994, Hashimoto et al. 1996). Yet the role of B. 
burgdorferi as a causative agent in these diseases is highly questionable in the light of several 
negative findings with culture (Raguin et al. 1992, Aberer et al. 1996), with PCR (Ranki et al. 
1994, Dillon et al. 1995, Wienecke et al. 1995, De Vito et al. 1996, Colome-Grimmer et al. 
1997) or with both methods (Meis et al. 1993, Alonso-Llamazares et al. 1997). 
 
CSF. A broad range of sensitivity values (14 to 100%) is found in PCR studies of CSF samples 
(Debue et al. 1991, Luft et al. 1992, Amouriaux et al. 1993, Liebling et al. 1993), the median 
sensitivity being 24% (Dumler 2001). This may be due to the low levels of organisms present 
in the CSF (Jaulhac et al. 1991, Christen et al. 1995), and/or the selection of patients. Patients 
with early NB are more readily found positive by PCR than patients in the later stages of 
disease (Lebech and Hansen 1992). These findings are in agreement with culture results, and 
the recovery rates may be low because the spirochaetes adhere to tissues. Furthermore, children 
with NB generally seem to have a much lower PCR positivity in the CSF (Feder and Hunt 
1995). 
 
Blood. In the blood, spirochaetemia is transient, and high detection rates can be expected only 
during the short period of primary infection. Due to the ability of B. burgdorferi to bind to 
activated platelets within the host (Coburn et al. 1993), the number of organisms is higher in 
plasma than in serum (Goodman et al. 1995). In blood or plasma, the overall sensitivity, 
regardless of stage of infection, is suggested to be 18% (Goodman et al. 1995), varying from 
9.5% of the patients with single EM to 40% of the patients who have both multiple skin lesions 
and systemic symptoms (Dumler 2001).  
 
Synovial fluid. PCR is sensitive for identification of B. burgdorferi DNA in the synovial fluid 
(SF) of patients with LA (Liebling et al. 1993, Bradley et al. 1994, Nocton et al. 1994, Persing 
et al. 1994). The sensitivity varies between 23 and 100%, depending on the choice of the 
multiplied target, the median sensitivity being 65% (Dumler 2001). The sensitivity of PCR in 
synovial tissue has been higher than in the SF (Jaulhac et al. 1996). B. burgdorferi DNA can be 
found in SF (and also in CSF) specimens of patients with late disease more than 10 years after 
infection (Keller et al. 1992, Lebech et al. 1992, Bradley et al. 1994, Nocton et al. 1994). 
 
Urine. In human urine, positive PCR results for diagnosis of LB have varied between 13 and 
100% (Priem et al. 1997, Brettschneider et al. 1998, Lebech et al. 2000, Dumler 2001). The 
usefulness of urine in the laboratory diagnosis of LB has, however, been controversial. This 
may stem from difficulties in preparation of adequate quality DNA from urine. 
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Other tissues. B. burgdorferi DNA has also been found in the vitreous fluid (Karma et al. 1993, 
Karma et al. 1995), in conjunctival specimens (Mikkilä et al. 1999), in the ligament tissue of a 
patient with chronic LB (Häupl et al. 1993), and in the breast milk of lactating women with EM 
(Schmidt et al. 1995). 
 
2.5.4 Serological methods
 
2.5.4.1 Enzyme-linked immunosorbent assay (ELISA)
 
ELISA has become the most commonly used technique for the serodiagnosis of LB. B. 
burgdorferi has numerous immunologically relevant antigens. The early immune response is 
directed against the FlaB protein (p41) (Craft et al. 1984) as well as against OspC (Wilske et al. 
2000) and BBK32 (Fikrig et al. 1998, Heikkilä et al. 2002b, Revel et al. 2002). Other borrelial 
antigens are listed in Table 4. Of these, p83/p100, p58, p43, p39, p30, p21, Osp 17, p14 in 
addition to OspC and flagella are important in the European context (Hauser et al. 1997). Many 
of the diagnostically relevant proteins of B. burgdorferi have a considerable interspecies 
variability, which leads to unpredictable reactivity with patient sera. In Europe, B. afzelii 
strains (e.g. strain PKo) have had the highest degree of sensitivity. In cases of NB, inclusion of 
B. garinii may further increase the diagnostic sensitivity (Wilske et al. 2000).    
 
Routine laboratory testing uses ELISA with borrelial whole-cell lysate (WCL) or flagella as the 
most commonly used antigens in Europe. Flagella as an antigen has an increased sensitivity of 
ELISA as compared to WCL (Hansen and Åsbrink 1989). However, several difficulties 
complicate LB serology. Anti-flagella antibodies often show a delayed rise during the early 
stages of LB. Even at the late stage of LB, 5 to 10% of patients do not have elevated antibody 
levels to either flagella or WCL (Oksi 1995), perhaps because of diversion of the host immune 
response towards Th1 immunity by borrelial factors (Infante-Duarte et al. 2000). The 
specificity of ELISA both with flagella and with WCL is insufficient. Viral infections cause 
false-positive IgM results in several LB tests (Brown et al. 1999). Differentiation between 
active and past infection is also problematic. Although a significant decline in the level of IgG 
antibodies to flagella has been observed (Wahlberg et al. 1994) after apparently successful 
treatment, antibody levels often remain high even for prolonged periods (Craft et al. 1984, 
Feder et al. 1992, Hammers-Berggren et al. 1994a and 1994b, Lomholt et al. 2000, Kalish et al. 
2001). Specific demonstration of serum immune complex by enzyme immunoassay (EIA) 
using WCL (Brunner and Sigal 2001) or OspA, OspB and OspC (Schutzer et al. 1999) as 
antigens has been suggested for diagnosing early and/or active LB.  Independent confirmation 
of these results is lacking. 
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Table 4. Relevant immunodominant proteins of B. burgdorferi, their function or localisation, 
and references when the protein has been used as a recombinant antigen.  
Protein/(MW) Known function or 
localisation 
Used as recombinant protein/reference 
p83/100
(83-100 kDa) 
Protoplasmic cylinder or 
flagellum-associated? 
Rauer et al. 1995, Burkert et al. 1996, 
Kaiser and Rauer 1998 and 1999 
HSP60, HSP75 
(60-75 kDa) 
Heat shock proteins  
p66 (66 kDa) Membrane-associated 
porin
p58 (58 kDa) Unknown  
BBK32/p35  
(47 kDa) 
Fibronectin-binding 
protein
Fikrig et al. 1997, Heikkilä et al. 2002b 
p41 (41 kDa) Flagellin Kaiser et al. 1993, Magnarelli et al. 1996 
and 2000 
BmpA/p39  
(39 kDa) 
Membrane-associated Oksi et al. 1995, Roessler et al. 1997, 
Magnarelli 2000 
FlaA  
(37-38 kDa) 
Flagellin A Gilmore et al. 1999 
BBK50/p37  
(37 kDa) 
Unknown Fikrig et al. 1997 
VlsE (35 kDa) Surface-exposed 
lipoprotein
Lawrenz et al. 1999, Magnarelli et al. 2002 
OspB (34 kDa) Outer membrane protein Magnarelli et al. 1996 and 2000 
OspA (31 kDa) Outer membrane protein Magnarelli et al. 1996 and 2000 
p30 (30 kDa) Unknown  
OspF  
(26.1 kDa) 
Outer membrane protein Magnarelli et al. 1996 and 2000, Hefty et al. 
2002
OspC
(21-24 kDa) 
Outer membrane protein Theisen et al. 1993, Fung et al. 1994, Padula 
et al. 1994, Mathiesen et al. 1998a and 
1998b, Rauer et al. 1998 
p22 (22 kDa) Unknown Magnarelli et al. 2000 
p21 (21 kDa) Unknown  
OspE
(19.2 kDa) 
Outer membrane protein, 
complement factor H- 
binding 
Magnarelli et al. 1996 and 2000, Hefty et al. 
2002
Osp17/DbpA
(17-18 kDa) 
Outer surface protein, 
decorin-binding protein 
Jauris-Heipke et al. 1999, Heikkilä et al. 
2002c
p41 int
(14 kDa) 
Internal flagellin 
fragment 
Burkert et al. 1996, Hauser et al. 1997, 
Rauer et al. 1998, Kaiser and Rauer 1999 
The close homology of Osp17 (published by Jauris-Heipke et al. 1999) and DbpA from the B. afzelii strains 
(Heikkilä et al. 2002c) suggests that these proteins represent species-specific variants of the same protein.
Several recombinant borrelial antigens (Table 4) and the chimeric borrelial proteins OspA, 
OspB, OspC, flagellin (p41), and p93 (Gomes-Solecki et al. 2000) have been studied to 
improve the serological diagnosis. Of these proteins, BmpA (Roessler et al. 1997) and OspC 
(Fung et al. 1994, Padula et al. 1994, Mathiesen et al. 1998a and 1998b, Rauer et al. 1998) 
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have been suggested as antigens, which induce early IgM responses. IgG antibodies to 
recombinant BmpA have been detected mainly in long-standing disease (Oksi et al. 1995, 
Roessler et al. 1997). A limiting factor in the use of OspC as a diagnostic antigen is the 
extensive structural variation of the molecule between borrelial species (Jauris-Heipke et al. 
1995, Livey et al. 1995). Use of recombinant antigens has increased the specificity of 
serological assays, but the sensitivity of tests using single antigens has thus far remained 
disappointing. A comparison of the sensitivity of laboratory methods in the different clinical 
manifestations of LB is shown in Table 5. 
  
  
Table 5. Sensitivity of different laboratory methods.  
____________________________________________________________________________  
Manif./ ELISA Culture PCR Reference 
sample 
____________________________________________________________________________ 
 
EM 
 Serum 20-50%   Wormser 1992*, Strle 1996*, Wilske
 Skin  38-80% 60-90% 2000*, Steere 2001*, Berger 1992**, 
     Robertson 1999**,  Schwartz 1992***,
     von Stedingk 1995***  
          
NB 
 Serum 70-90%  Kaiser 1998*, Oschmann 1998*, 
CSF 50-90% <10% 25% Steere 2001*, Karlsson 1990**,   
    Eiffert 1995*** 
 
LA 
 Serum 90-100%  Priem 1997*, Wilske 2000*,   
 SF <5% 50-70% Persing 1994**, Eiffert 1998***,  
    Vasiliu 1998***  
  
ACA  
 Serum 95-100%   Åsbrink 1985*, Preac-Mursic 
 Skin  20-60% 60-90% 1985**, Åsbrink and Hovmark 
     1985**, Picken 1998**, Melchers 
      1991***, Moter 1994***  
      
____________________________________________________________________________ 
*ELISA, **culture, ***PCR 
 
 
2.5.4.2 Western blotting (WB)
 
WB is today mainly used as a confirmatory assay in the serodiagnosis of LB when the 
screening assay (ELISA) is indeterminate. In the United States, a two-step approach is 
generally recommended (Dressler et al. 1993, Johnson et al. 1996). WB using WCL offers a 
great number of immunoreactive bands corresponding to different borrelial proteins. A 
disadvantage is the difficulty of distinguishing between specific and cross-reactive bands. In 
WBs using recombinant antigens, specific proteins are selected, and homologous proteins of 
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different species can be combined (Wilske et al. 1994, Roessler et al. 1997). Furthermore, 
truncated recombinant antigens, which lack cross-reactive domains, e.g. the internal flagellin 
fragment, can be used (Wilske et al. 1993a). However, WBs using recombinant antigens have 
so far not been as sensitive as WBs using WCL (Wilske et al. 2000).  
 
The interpretation criteria in the United States and in Europe differ from each other. In the 
United States the rules refer to the whole-cell antigen of a B. burgdorferi sensu stricto strain 
(Dressler et al. 1993, Engström et al. 1995). The IgG blot is, according to the CDC criteria 
(CDC 1995), defined as positive if >5 bands of the proteins 18, 21 (OspC), 28, 30, 39 (BmpA), 
41 (Fla), 45, 59, 66, 93 kDa are detectable. The IgM blot will be considered positive if >2 
bands of the proteins OspC, 39 kDa (BmpA), 41 (Fla) are detectable. These rules were 
developed for surveillance purpose, not for clinical decision-making. In Europe, with a more 
clinically oriented aim, some authors have demonstrated that the rules for interpretation must 
be defined strain-specifically (Hauser et al. 1997, Hauser et al. 1999, Kaiser and Rauer 1999). 
These criteria for a positive IgG WB using the B. afzelii strain PKo include positivity for at 
least two of the bands p83/100, p58, p43, p39, p30, OspC, p21, Osp17 or p14. For a 
recombinant IgG blot, a two-band criterion is recommended, as well. The respective criteria for 
IgM WB with the B. afzelii strain PKo include positivity for at least one of the bands p41, p39, 
OspC or Osp17. Recently, a European multicentre study compared WB results of 227 serum 
samples from 9 laboratories in different countries (Robertson et al. 2000). No useful single rule 
resulted from this study but finally, five nearly similar rules that gave acceptable sensitivities 
and specificities were formulated from a subset of eight bands of common importance.  
 
2.5.4.3 Indirect immunofluorescence assay (IFA)
 
IFA is also used for detection of specific IgG and IgM antibodies. In order to diminish cross-
reactivity with common spirochaetal antigens, improved specificity is achieved by 
preabsorbing sera with Reiter treponemes (Wilske et al. 2000). The sensitivity and specificity 
of IFA has been shown by some authors to be similar to those obtained with ELISA (Russell et 
al. 1984, Magnarelli et al. 1984). However, some other authors find IFA to be less sensitive 
than ELISA, and too laborious for high-volume testing (Stiernstedt et al. 1985, Golightly 1993, 
Tilton 1994) because it is more difficult to automate and the readings are more subjective than 
those of ELISA (Magnarelli et al. 1984, Russell et al. 1984).  
 
2.5.5 Lymphocyte proliferation test
 
B. burgdorferi usually induces also a cell-mediated immune response, which can be analysed 
in vitro by the lymphocyte proliferation test (Dattwyler et al. 1986). This test may be helpful in 
the diagnosis of late LB in a small subset of patients with weak antibody response or none. It 
has also been proposed for patients whose LB diagnosis has been based on the presence of EM 
but who, after treatment, developed a clinical picture of late LB (Dattwyler et al. 1988, 
Dressler et al. 1991). However, this assay has been shown to have a large number of false- 
positive reactions in healthy control patients due to cross-reactivity against microbes 
antigenically resembling B. burgdorferi (Zoschke 1992) and it is considered less sensitive than 
the measurement of antibodies (Dattwyler et al. 1988). A comparison of laboratory methods is 
shown in Table 6. 
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Table 6. Comparison of methods in the laboratory diagnosis of LB. 
____________________________________________________________________________ 
Method Use/usefulness    Disadvantages 
____________________________________________________________________________ 
Culture Gold standard for diagnosis Low sensitivity, time-consuming 
 EM, research Fastidious organism 
   
PCR Confirmatory test Risk of false-positives  
 Research Sensitive only from skin biopsies 
    
ELISA Routine assay for serum/CSF  Insufficient specificity and sensitivity
       Interlaboratory variability   
 
WB Confirmation of equivocal ELISA  Cross-reactive bands   
 results Results based on subjective analysis, 
   laborious 
 
IFA A screening test for IgG and IgM Too laborious for high-volume testing 
 antibodies (serum/CSF) Less sensitive than ELISA 
____________________________________________________________________________ 
2.5.6 Diagnosis of neuroborreliosis
The assessment of the diagnosis of NB involves essential differences compared with that of 
other manifestations of LB. In addition to clinical symptoms, a positive IgG ELISA result and 
pleocytosis in the CSF are needed to confirm the diagnosis of NB. Detection of pathogen-
specific, intrathecally produced antibodies, i.e. an elevated CSF/serum antibody index (AI), is 
important. Especially in the early stage of LB, only the CSF findings may be positive, while 
the serum antibodies are still negative. In rare cases the situation may be the opposite (Garcia-
Monco and Benach 1995). IgM antibodies are usually elevated in the early stage of NB, but 
false-positive reactions, due to cross-reactive immunity, may also cause problems in the CSF 
analysis. PCR from the CSF may be used in cases with negative or borderline serological 
results but the sensitivity of PCR may limit its´ use.  
 
There is usually a good correlation between clinical recovery from NB and the disappearance 
of intrathecally produced IgM antibodies against B. burgdorferi. However, persistent specific 
intrathecal IgM synthesis for more than one year after treatment is also shown despite complete 
clinical recovery (Hammer-Berggren et al. 1993). A positive CSF/serum IgG antibody index 
may be detectable years after successful treatment (Wilske et al. 1986, Kruger et al. 1989, 
Hammers-Berggren et al. 1993). Consequently, the finding of intrathecal IgM and IgG 
production against B. burgdorferi must always be evaluated in relation to clinical data and 
signs of inflammation in the CSF, and does not necessarily indicate active NB or the need of 
further antibiotic treatment. Therefore, follow-up of intrathecal antibodies may not be useful 
after the patient´s clinical condition has normalised.
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3 AIMS OF THE STUDY
 
The general aim of the study was to improve the specificity and sensitivity of the laboratory 
diagnosis of Lyme borreliosis by using both conventional and new recombinant antigens.  
 
The specific aims of the study were: 
 
I To assess the usefulness of antibodies to flagella of B. afzelii as a serological marker of 
disease activity or successful treatment response. 
 
II To explore the molecular structure/the amino acid sequences of flagellin A proteins in 
Finnish Borrelia strains representing three pathogenic species, and to analyse the 
antigenicity of recombinant flagellin A proteins.  
 
III To analyse three new variants of recombinant OspC proteins in LB serodiagnosis with 
special emphasis on the IgM serology. 
 
IV To analyse antibodies to recombinant DbpA, BBK32 and OspC proteins, and IR6 
peptide as antigens in the analysis of cerebrospinal fluid samples from neuroborreliosis 
patients. 
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4 MATERIALS AND METHODS 
4.1 PATIENTS
4.1.1  Erythema migrans (II, III) 
Seventeen culture-positive EM patients from Finland with both acute and convalescent samples 
were available (13 B. afzelii and 4 B. garinii). Nine of the samples were received from Åland 
Central Hospital and eight were collected in collaboration with health centres from the coastal 
area around Helsinki. Collecting these eight further samples was part of a questionaire-based 
study organized during the years 1999-2001. 
4.1.2 Neuroborreliosis (I, II, III, IV) 
All the patients had neurological symptoms and/or signs compatible with NB. The clinical 
diagnosis of NB was confirmed by demonstrating IgG antibodies against flagella in the sera 
and in the CSF by ELISA, and by elevated leucocytes in the CSF. Patients represented both 
early and late stages of NB. In publication I only late stage disease was evaluated. In 
publication IV the criteria mentioned above (pleocytosis and elevated antibodies in the CSF) 
were not always fulfilled at an early stage of NB but as the medical history and clinical features 
of the patients were suggestive for NB, these patients were classified as probable or possible 
NB (Table 7). The numbers of NB patients were 35, 19, 15, and 89 in publications I to IV, 
respectively. Both sera and CSF samples were evaluated. 
Table 7. Classification of the 89 patients with neuroborreliosis. 
Combination of laboratory 
findings 
Duration of 
symptoms 
Confirmed 
n=31
- elevated anti-flagella IgG 
antibodies in CSF 
< 3 mo, n=30 
> 3 mo, n=0  
 - pleocytosis in CSF (>5x106/l)  
 - anti-flagella IgG and/or IgM anti- 
bodies in serum 
Probable 
n=18
- elevated anti-flagella IgG 
antibodies in CSF 
< 3 mo, n=8 
> 3 mo, n=7 
 - no pleocytosis in CSF  
 - anti-flagella IgG and/or IgM anti- 
bodies in serum 
Possible  
n=40
- pleocytosis in CSF (n=2) or
- erythema migrans plus facial palsy   
without positive laboratory 
findings  (n=3) or
- anti-flagella IgG and/or IgM anti- 
bodies in serum (n=35) 
< 3 mo, n=22 
> 3 mo, n=18  
33
4.1.3 Lyme arthritis (I, II, III) 
Altogether, 24, 19 and 15 patients with LA were included in publications I, II and III, 
respectively. The clinical diagnoses were confirmed by demonstrating antibodies against 
flagella and WCL in the sera by ELISA. 
4.1.4 Other LB samples  
Three patients with ACA, a rare form of LB, and six patients with myositis were presented in 
publication I.  
4.1.5 Control samples (II, III, IV) 
As control samples, we used sera from patients with syphilis (n=10), Epstein-Barr virus (EBV) 
infection (n=15), rheumatoid factor (RF) positivity (n=10), antistreptolysin (ASO) positivity 
(n=10), high Salmonella (n=10) or Yersinia enterocolitica (n=10) antibody titres with positive 
stool culture, clinically and serologically verified systemic lupus erythematosus (SLE) (n=10), 
and samples from healthy blood donors (n=27) (II, III). Control CSF samples were from 
patients with syphilis (n=14), from patients with other neurological diseases (n=32), and from 
patients without proven infections (n=20) (IV).  
4.2 BORRELIAL STRAINS
As genomic sources for recombinant proteins we used domestic borrelial strains of B. 
burgdorferi sensu stricto, isolated from the CSF, and B. afzelii and B. garinii isolated from skin 
biopsies of Finnish patients with LB (Junttila et al. 1999). For flagella antibody determinations, 
the material stemmed from B. afzelii DK1, as provided by the kit (Dako). IR6 peptide based on 
the published sequence (Liang and Philipp 2000) was produced by the Core Facility of the 
Haartman Institute, University of Helsinki. 
4.3 CULTURE AND DNA ISOLATION OF BORRELIA 
Domestic borrelial strains were cultured in Barbour-Stoenner-Kelly-H (BSK-H) medium 
(Sigma Chemical Co., USA) at 33°C in a 5% CO2 atmosphere until growth was approximately 
1-2x108 cells/ml. The genomic DNA was then isolated using the DNeasy Tissue Kit (Qiagen, 
Germany). 
4.4 POLYMERASE CHAIN REACTION 
A PCR-based approach was used to amplify and sequence the genes from different isolates of 
B. burgdorferi sensu lato. Primers for gene amplification were designed on the basis of 
published data (Tilly et al. 1997, Gilmore et al. 1999). Several primer pairs were designed and 
tested to ensure that the entire coding sequences of the genes were obtained. For each borrelial 
strain, the gene sequences were generated by PCR amplification of B. burgdorferi genomic 
DNA. Approximately 1 ng of template DNA was used in standard PCR conditions: 30 cycles 
of 94°C denaturing for 1 min, 50°C annealing for 1 min, and 72°C extension for 1 min 30 s 
with AmpliTaqGold DNA polymerase (Perkin Elmer, USA), followed by a final extension of 
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10 min at 72°C. DNA products were visualized by gel electrophoresis on 1% agarose NA gel 
(Amersham Pharmacia, Sweden) containing ethidium bromide. To eliminate any errors caused 
by Taq-polymerase, cloning and sequencing of the genes were done twice or even three times, 
following discordant results. Primers for constructs were chosen individually from the 
sequences analysed and the PCR reaction was performed as above.  
4.5 CLONING OF THE GENES 
The PCR products were cloned into pCR 2.1-TOPO vector (Invitrogen, The Netherlands). The 
E. coli host cell used for cloning was INFαF (Invitrogen). The work was carried out with 
approval number 21/L/98, (11/P/98) of the Finnish Board for Gene Technology.  
4.6 DNA SEQUENCING 
Plasmid DNA containing the gene inserts was isolated from E. coli by using a QIAprep-spin 
plasmid kit (Qiagen). DNA sequencing was performed with the DyePrimer (T7, M13Rev) 
cycle sequencing kit (Applied Biosystems Inc., USA) in accordance with the manufacturer’s 
instructions by the Core Facility of the Haartman Institute, University of Helsinki. Sequencing 
reactions were run and analysed with an automated sequencing apparatus model 373A 
(Applied Biosystems, Inc.). DNA and protein sequences were analysed with Lasergene 
software (DNASTAR, Inc., USA). 
4.7 EXPRESSION OF THE RECOMBINANT PROTEINS  
The gene constructs consisted of the coding sequence of the mature protein. The PCR products 
were cloned into pCR 2.1-TOPO vector. After digesting the purified pCR 2.1-TOPO plasmid 
with BamHI and KpnI (for BBK32 BamHI and XhoI), the cleaved gene was ligated into a 
similarly cut pQE-30 expression plasmid (Qiagen) with T4 ligase. The ligation mixture was 
used to transform E. coli M15 host cells as described in the manufacturer´s instructions 
(Qiagen). For BBK32, a similarly digested pGEX-4T-1 expression plasmid (Amersham 
Pharmacia) was generated and transformed into E. coli BL21 host cells. The transformation 
mixture was plated onto Luria-Bertani agar containing 100 µg ampicillin and 25 µg kanamycin 
per ml, and for BBK32 only 100 µg ampicillin. A primary culture for expression of the 
recombinant protein was started by inoculating a single colony from a fresh transformant plate 
to 50 ml of Luria-Bertani broth containing antibiotics as above. The culture was incubated at 
37°C overnight with shaking. This starter culture was diluted 1:100 to 1500 ml of Luria-
Bertani broth with antibiotics as above, incubated at 37°C for three hours (the growth reached 
the mid-log phase; the optical density at 600 nm was ca. 0.6). Isopropyl-β-D-thiogalactoside 
(Calbiochem, USA) was added to a final concentration of 0.6 mM, and further incubation was 
performed for three hours. The cells were then harvested, washed and sonicated. The expressed 
recombinant protein was attached via its 6xHistidin tag to a Chelating Sepharose Fast Flow 
column (Amersham Pharmacia) containing Ni2+, and was subsequently eluted from the column 
with 160 mM imidazole eluting buffer (rFlaA was eluted with 160 mM imidazole-4 M 
guanidine hydrochloride eluting buffer). Recombinant GST-BBK32 protein was similarly 
expressed and eluted with 30 mM glutathione. Purification was done on a Glutathione-
Sepharose Cl Column (Amersham Pharmacia). Protein expression was confirmed by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). 
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4.8 PURIFICATION OF THE RECOMBINANT PROTEINS AND MEASUREMENT OF
THE PROTEIN CONCENTRATION
rFlaA proteins were dialysed in 10 mM potassium phosphate (pH 7.2) and, after centrifugation, 
the resulting insoluble protein pellet was resolubilised in 4 M guanidine hydrochloride when 
used for WB and in 5 M urea when used for ELISA. The insolubility of the rFlaA protein 
complicated reliable measurement of the protein concentration by either spectrophotometry or 
chemical assay methods. For WB and ELISA, protein concentrations of rFlaA preparations 
were estimated by comparing the intensity of the FlaA bands with known concentrations of 
bovine serum albumin (BSA) in SDS-PAGE after Coomassie blue staining or Ponceau S 
staining after transfer to nitrocellulose.  
 
rOspCs were dialysed in 10 mM diaminopropane-HCl, pH 8.8, before purification by 
chromatography, in which protein was loaded onto a Poros HQ 20 column (PerSeptive 
Biosystems, USA) equilibrated with 10 mM diaminopropane, pH 9.2. A buffer gradient to 1 M 
NaCl-100mM Tris-HCl, pH 8.0 was used for elution. Fractions containing the protein were 
further purified by hydrophobic interaction with Butyl-Sepharose (Amersham-Pharmacia), 
loading at 1.2 M Na2SO4, followed by elution with a gradient to water. The concentration of 
rOspC was measured with the high-performance gel-permeation chromatography method in a 
Fractogel EMD column (Merck, Germany) that monitors UV absorption at 220nm (Hayakawa 
et al. 1997), with BSA as reference. This method was used because of the shortage of aromatic 
amino acids in OspCs.  
rDbpA was dialysed in 10 mM diaminopropane-HCl, pH 8.8, and further purified by 
chromatography in a MonoQ column. The rBBK32 protein eluted from the glutathione-S-
transpherase column was further purified by phenyl-TSK (HIC) hydrophobic interaction 
chromatography. The final purity of the recombinant proteins was confirmed by SDS-PAGE. 
4.9 BIOTINYLATION OF RECOMBINANT OspC AND THE IR
6
PEPTIDE
The purified rOspC proteins from the three strains were biotinylated with ImmunoPure-NHS-
Long chain biotin (Pierce, USA), which, dissolved in NN-dimethylformamide, was added to 
the purified rOspC protein and to Na2CO3, and rotated overnight at room temperature. The 
final concentrations of OspC, biotin, and Na2CO3 were 0.6 mg/ml, 0.15mg/ml, and 0.02 M, 
respectively.
 
Further purification and removal of free biotin was done with gel permeation 
chromatography on a Superose 12 column (Amersham Pharmacia) in 0.1M Na2SO4. IR6 was 
aminoterminally biotinylated by the Core Facility of the Haartman Institute. 
4.10 ENZYME-LINKED IMMUNOSORBENT ASSAYS
For ELISA with rOspC and IR6 peptide, the plate wells were initially coated with 0.05 µg of 
streptavidin (Boehringer Mannheim, Germany) in PBS overnight at +4°C. After washing, 
approximately 30 ng/well of biotinylated rOspC in bovine serum albumin (BSA) 5mg/ml in 
155 mM NaCl-0.04% Tween 20 buffer (BSA-NaCl-Tween) was added for 2 h at room 
temperature. For ELISA with IR6 peptide, 100 µl of human serum albumin (HSA) in PBS-
NaN3 buffer was added without previous washing and, after 2 h at +37°C, the IR6 peptide was 
added at 1:10 000 dilution in PBS-0.04 % Tween- 0.04 % NaN3 buffer for 2 h at room 
temperature. For rDbpA and rBBK32 ELISA, each well was coated overnight at +4°C with 
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200 ng of protein, rDbpA diluted in PBS and rBBK32 in 3 M urea. After these steps, with 
intervening washes the following reagents were sequentially incubated on the plates: serum 
samples at 1:100 dilution (or 1:200 for FlaA and OspC in works II and III, respectively) and 
CSF samples at 1:10 dilution in BSA-NaCl-Tween (OspC in work III alternatively in 0.1 M 
NaSCN-BSA-NaCl-Tween) overnight at +4°C for other antigens than IR6, which was diluted 
in HSA (5 mg/ml) in 0.05 % Tween-1 mM benzamidine-0.2 mM PMSF-0.06 % NaN3 buffer 
for 2 h at room temperature, alkaline phosphatase-conjugated rabbit anti-human IgM or IgG 
(Jackson Immuno Research Laboratories Inc., USA) at 1:5000 dilution in BSA-NaCl-Tween 
for 2 h, and 4-nitro-phenylphosphate (Boehringer Mannheim) substrate in diethanolamine 
buffer pH 10.0 for 15 to 30 min. The absorbance at 405 nm was measured with a Multiscan 
photometer (Thermo Labsystems, Finland).  
 
IgM and IgG antibodies against borrelial flagella were measured with a commercial flagellin-
based ELISA kit (Dako) modified by using end point titration of the antibodies, as described 
earlier (Seppälä et al. 1994, Peltomaa et al. 2000). Briefly, sera and CSF samples were diluted 
serially in three-fold steps for the test and applied to the plates for overnight incubation. The 
bound antibodies were detected by biotin-labeled goat anti-human IgM and IgG (Zymed, USA) 
and alkaline phosphatase-labeled streptavidin (Zymed). An end point titre was obtained at an 
optical density (OD) level determined with a cut-off control provided by the kit.  
4.11 WESTERN BLOTTING
Western blotting was done in publication II with rFlaA. rFlaA was applied to SDS-PAGE on 
12.5% gels and transferred to a nitrocellulose membrane (Bio-Rad, USA) by semi-dry transfer 
with 40 mM Glycine-50 mM Tris (pH 9.0)-0.375 % (w/v) SDS-20 % (v/v) methanol buffer. 
For IgM WB, serum samples were incubated at 1:500 dilution in BSA -NaCl-Tween for 2h. For 
IgG WB, serum dilution 1:75 in 0.1% Tween 20-0.9% NaCl was used. After washing, the blots 
were incubated with alkaline phosphatase-conjugated rabbit anti-human IgM or IgG (Jackson 
Immuno Research Laboratories Inc.) for 2h. In control experiments the anti-IgM conjugate 
showed a faint FlaA band in the absence of serum. Therefore, the conjugate was absorbed with 
rFlaA from B. afzelii. FlaA in coupling buffer (0.6 M NaCl-125 mM NaHCO3) was added to 
Tresyl-activated Sepharose 4B (Amersham Pharmacia) beads. After incubation for 16 hours 
and centrifugation the beads were washed with the coupling buffer, and the conditions were 
alternated three times between 0.1 M Tris buffer (pH8.0)-0.5 M NaCl and 0.1 M acetate buffer 
(pH 4.0)-0.5 M NaCl. The IgM conjugate was added to the beads and centrifuged after 
incubation for 2 h. The supernatant was used at 1:8000 final dilution for the IgM WB. The IgG 
conjugate was used without FlaA immunoabsorption at 1:5000 dilution. After washing, the 
visualisation was done with 5-bromo-4-chloro-3-indolylphosphate-Nitro Blue Tetrazolium 
(Sigma Chemical Co.). The intensity of the WB bands was evaluated visually and with 
MacBAS 2.5 software (Fujifilm, Japan). In MacBAS programme the mean of the intensity 
values of the blood donor samples was calculated. Values above the mean plus 2 SD were 
defined as positive.  
4.12 STATISTICAL METHODS
The Microsoft Excel 2000 programme (Microsoft, USA), the Statview 4.5 programme (Abacus 
concepts, USA), and the GraphPad PRISM 3.0 programme (GraphPad Software, Inc., USA) 
were used for calculations of standard statistics. 
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5 RESULTS
5.1 ANTIBODIES TO FLAGELLA AS A MARKER OF SUCCESSFUL TREATMENT (I)
The purpose of the study was to find a specific serological marker distinguishing between 
successful treatment of late LB and therapy-resistant persistent disease activity. Consecutive 
serum samples from 68 treated patients from the Åland Islands with late LB were analysed 
during a 1 to 2 year follow-up period after the start of treatment. These patients were divided 
into groups, depending on the clinical outcome of the treatment. Clinical evaluation of the 
patients was done at Åland Central Hospital. End-point enzyme immunoassay titres of IgG1, 
IgG2, IgG3, and combined IgG1+3 subclasses against a sonicate antigen of B. afzelii were 
determined and compared with the IgG antibody response against B. afzelii flagella. Individual 
half-lives of the antibody levels were calculated for each patient, and the half-life values were 
compared with the patients´ clinical outcome. Antibodies to flagella decreased markedly after 
successful treatment, with a half-life of 112 (+/-92) days (arithmetic mean value+/-SD). This 
was significantly shorter than the half-life in patients with unsuccessful treatment (271 (+/- 
151) days), (p<0.0001). The decrease was observed mainly in the IgG1 and IgG4 responses to 
flagella. The levels of combined IgG1+3 subclass antibodies against the WCL antigen and the 
individual levels of IgG1, IgG2, and IgG3 antibodies did not change significantly after 
treatment.  
5.2 DNA AND AMINO ACID SEQUENCES OF BORRELIAL GENES AND THE
RESPECTIVE PROTEINS
5.2.1 Flagellin A (II)
The sequences of flaA from various strains were highly homologous. A comparison with the 
published flaA sequences of B. burgdorferi sensu stricto strains B31 and 212 showed that flaA 
of the B. burgdorferi sensu stricto strain ia was identical with that of the American strain B31, 
whereas it differed by nine nucleotides from the flaA sequence in strain 212. The identity of 
flaA sequences between the Finnish strains B. burgdorferi sensu stricto ia and B. afzelii A91, 
between B. burgdorferi sensu stricto ia and B. garinii 46, and between B. afzelii A91 and B. 
garinii 46 was 93, 92, and 93%, respectively. The identity of flaA in B. afzelii A91 and in B. 
garinii 46 compared to flaA in strain 212 was 92 and 91%, respectively.  
At the protein level, the deduced amino acid sequences of FlaA from B. burgdorferi sensu 
stricto ia, from B. afzelii A91, and from B. garinii 46 were 95% identical. The flaA gene of B. 
garinii 46 had an additional triplet of nucleotides, AAA, at position 1000 to 1002, leading to a 
lysine insertion into an also otherwise hydrophilic sequence area (Fig 3). None of the sequence 
differences changed the local hydrophilicity of the sequence area, indicating conservation of 
the overall structure. The deduced amino acid sequence of the FlaA protein (without the leader 
peptide) was rich in phenylalanine and tyrosine (15 and 16 amino acids, respectively), but 
contained no cysteine. The count of these amino acids was identical in all three FlaA proteins 
examined in this study. Thirty-three per cent of the deduced amino acids were hydrophobic. 
The calculated isoelectric points of FlaA from strains ia, A91, and 46 for the mature protein 
without leader sequence were 5.70, 5.33, and 7.27, respectively. Three additional lysines and 
fewer aspartic acids in FlaA from B. garinii 46 as compared with FlaA
 
from B. burgdorferi 
sensu stricto ia and B. afzelii A91 may account for the higher isoelectric point of the first 
mentioned. 
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Fig. 3. FlaA amino acid sequence comparison of the translated full-length gene in B. burgdorferi sensu stricto 
strains B31, 212 and ia (Bbia), B. afzelii A91 (BaA91) and B. garinii 46 (Bg46). Boxes indicate amino acid 
heterogeneity. The starting point of our recombinant constructs is indicated by an arrow.  
5.2.2 OspC (III)
The identity of the ospC nucleotide sequences between the Finnish strains ia, A91, and 40 was 
76 to 81%. The deduced amino acid sequences were 57 to 73% identical. Four amino acid 
deletions were observed in the OspC sequence comparison in both B. burgdorferi ia and B. 
garinii 40, and three in B. afzelii A91. Although these deletions were distributed in different 
parts of the molecules, three of them both in ia and A91, and one in 40 were in hypervariable 
regions of OspC (Livey et al. 1995). The C-terminal peptide in OspC of B. burgdorferi ia and 
B. afzelii A91 was identical with the immunogenic C-terminal decapeptide PVVAESPKKP 
described by Mathiesen et al. (1998b), whereas in OspC of B. garinii 40 the serine was 
replaced with threonine. Thirty to thirty-three per cent of the deduced amino acids were 
hydrophobic. OspC of B. burgdorferi ia and B. garinii 40 contained two, and OspC of B. afzelii 
A91 three phenylalanines. Only OspC of ia
 
had one tyrosine, and tryptophane was not present 
in any of the proteins. One cysteine was present in all three proteins, and there were three, two, 
and four histidines in OspC of ia, A91, and 40, respectively. The calculated isoelectric points 
of the mature non-acylated forms in OspC of ia, A91, and 40 were 7.96, 8.33, and 7.16, 
respectively.  
The sequences encoding the mature proteins of the three OspCs were compared with the 
sequences of the 16 OspC serotypes established by Wilske et al. (1996b), except for strain 
Pstm, which was not found in the GenBank database (Fig. 4). Among these strains, OspC of B. 
afzelii PLe showed 98.4 per cent identity with OspC
 
A91 and B. garinii WABSou 99.5 per cent 
identity with OspC
 
40
 
at the protein level. The OspC sequence of B. afzelii ACA1 was identical 
with OspC
 
A91, the OspC of B. garinii W was identical with OspC
 
40, and the OspC of B. 
burgdorferi sensu stricto B31 was identical with OspC
 
ia (at the nucleotide level these last 
differed from each other by one nucleotide).  
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Fig. 4. Comparison of OspC sequences with close homology: the mature proteins of B. burgdorferi sensu stricto 
strain ia (Bbia), B. afzelii strains A91 (BaA91), PLe and DK9, and B. garinii strains 40 (Bg40), WABSou and 
PHei. Boxes indicate amino acid heterogeneity.
5.3 NEW ANTIGENS IN THE  LABORATORY DIAGNOSIS OF LYME BORRELIOSIS 
5.3.1 Flagellin A (II) 
For IgG serodiagnosis of NB and LA, FlaA appeared to be a sensitive antigen (Table 8). 
Seventy-one or seventy-four percent of patients with NB were positive either by WB or 
ELISA, respectively. The corresponding positivities for the LA patient samples were 86 and 
79%. Serum samples from patients with syphilis and SLE showed mild cross-reactivity in IgG 
tests. Although the sequences of the three FlaA proteins were highly homologous, the 
immunoreactivity in Finnish patient sera was stronger against rFlaA from B. garinii and B. 
afzelii than against rFlaA from B. burgdorferi sensu stricto.
In the serodiagnosis of EM, neither IgG nor IgM ELISA was sensitive. For this patient group, 
the sensitivity of the IgM serology in WB and ELISA assays was only 20 to 27%, and in IgG 
serology 13 to 20%. With IgM ELISA, 58 and 37% of patients with NB and LA, respectively, 
were positive. Cross-reactive antibodies to FlaA, especially in serum samples from patients 
with RF positivity and EBV infection, reduced the specificity of the IgM serodiagnosis.  
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Table 8. Positive IgG and IgM ELISA results with recombinant FlaA and OspC compared 
with flagella. For rOspC IgM ELISA, the combined results of three ELISAs using NaSCN 
were used.  
 
  
IgG 
  
IgM 
 
Antigen EM NB LA EM NB LA 
 n=15 n=19 n=19 n=15 n=19 n=19 
FlaA       
afz 1 (6%) 12 (63%) 13 (68%) 2 (13%) 5 (26%) 4 (21%) 
gar 2 (13%) 14 (74%) 13 (68%) 4 (27%) 8 (42%) 2 (11%) 
ss 2 (13%) 3 (16%) 8 (42%) 2 (13%) 9 (47%) 6 (32%) 
tot 3 (20%) 14 (74%) 15 (79%) 4 (27%) 11 (58%) 7 (37%) 
 n=17 n=15 n=15 n=17 n=15 n=15 
OspC       
afz 6 (35%) 4 (27%) 7 (47%) 4 (24%) 4 (27%) 6 (40%) 
gar 1 (6%) 3 (20%) 3 (20%) 6 (35%) 8 (53%) 5 (33%) 
ss 3 (18%) 5 (33%) 3 (20%) 4 (24%) 5 (33%) 5 (33%) 
tot 6 (35%) 5 (33%) 9 (60%) 6 (35%) 8 (53%) 8 (53%) 
 
n=17 n=15 n=15 n=17 n=15 n=15 
Flagella 4 (23%) 14 (93%) 15(100%) 4 (23%) 7 (47%) 5 (33%) 
Afz = B. afzelii, gar = B. garinii, ss = B. burgdorferi sensu stricto and tot = total number of patients in each group 
with antibodies to any subspecies of the respective protein.  
5.3.2 OspC (III)
Results of IgM and IgG ELISAs with rOspC were compared with ELISA using flagella as 
antigen (Table 8). In EM, 30 to 35% of the patients´ samples reacted with one or more of the 
rOspCs in the acute or convalescent phase, respectively, both with IgM and IgG ELISA. Of the 
patients, 53% with NB and 53% with LA had IgM antibodies to OspC, whereas 33% with NB 
and 60% with LA had IgG antibodies to OspC. Cross-reactive antibodies to rOspC in IgM 
ELISA were observed in serum samples from patients with RF positivity, and with syphilis or 
EBV infection. Using thiocyanate, the number of false-positive EBV samples decreased from 
11 to 7 of 17, and all the values for the EBV samples remaining above the cut-off value were 
low positives only (Fig. 5). The reproducibility of the test was evaluated by determining the 
coefficient of variation (CV) of the OD values in three separate rOspC IgM ELISA 
experiments. The total CV was 10.3% when BSA was used and 7.9% when sodium thiocyanate 
(NaSCN) was present. In IgM serology the immunoreactivity was stronger against rOspC from 
B. afzelii and B. garinii than against rOspC from B. burgdorferi sensu stricto. 
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Fig. 5. IgM ELISA results with rOspC proteins from B. afzelii (A91) (panels A and B), B. garinii (40) (panels C 
and D) and B. burgdorferi sensu stricto (ia) (panels E and F) as antigens. The OD/cut-off values are shown 
without (NaSCN-) and with (NaSCN+) sodium thiocyanate. The OD/cut-off values from three distinct ELISA 
experiments for each patient and control sample are averaged. Serum samples were from patients with erythema 
migrans at the acute phase (EM1), erythema migrans at the convalescent phase (EM2), neuroborreliosis (NB), 
Lyme arthritis (LA), syphilis (SY), Epstein-Barr virus infection (EBV), rheumatoid factor positivity (RF+), 
systemic lupus erythematosus (SLE), and from healthy blood donors (BD). The level of positivity for OD/cut-off 
values (>1) is indicated by a line.  
 
The sensitivity of OspC IgG serology remained lower than that of the conventional flagella 
antigen (Table 8). Serum samples from patients with SLE and ASO positivity occasionally 
showed weak IgG cross-reactivity. rOspC from B. afzelii detected anti-OspC antibodies in IgG 
ELISA most frequently.  
 
Anti-OspC and flagella antibodies were evaluated in 17 LB patients during post-treatment 
periods at the acute and convalescent phases. This group included three patients with EM, 10 
with NB, and four with LA. In IgM ELISA with NaSCN-BSA buffer, 71% of the patients were 
positive with any of the rOspCs and 88% with flagella at the acute phase. In the convalescent 
phase, there were two seroreversions and two seroconversions towards rOspC, while nine 
patients had retained and one had gained IgM antibody positivity towards flagella. In IgG 
serology an increasing tendency of both rOspC and flagella antibody positivities were observed 
during the post-treatment period. 
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5.3.3 rDbpA, rBBK32, rOspC, and IR
6
peptide in neuroborreliosis (IV)
The aim of the study was to apply three variant recombinant antigens of DbpA, BBK32 and 
OspC, and the IR6 peptide in the diagnosis of NB. The performance of the new antigens was 
compared with that of the established method using intact flagella antigen. IgG ELISA was 
used for all antigens, and IgM ELISA for OspC and flagella. The 89 patients with NB were 
classified according to the laboratory findings in the CSF (Table 7). In IgG ELISAs, the 
sensitivities of the new antigens varied between 79 and 93%, compared to 57% for the flagella. 
The specificity of the new antigens varied from 92 to 98%. Of the patients with elevated anti-
flagella IgG antibodies in the CSF, 93% were positive for at least three new antigens. Of the 
patients with negative or borderline CSF anti-flagella antibodies, 51% were positive for at least 
three new antigens (Fig. 6).  
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Fig. 6. Results of IgG ELISAs with the recombinant antigens DbpA, BBK32, and OspC, and with the IR6 peptide 
in the CSF of patients with confirmed, probable or possible neuroborreliosis, and of controls, including patients 
with syphilis, other neurological diseases, and with no proven infection. The levels of positivity for OD/cut-off 
values (>1) are indicated by horizontal lines. The highest OD values for the variants of the indicated recombinant 
antigens were used in the analyses. 
In late NB, antibodies to DbpA and IR6 were seen more frequently than antibodies to OspC and 
BBK32. IgG antibodies to BBK32 were restricted to the CSF and to patients with early NB, 
suggesting, that antibodies to this protein might be a marker of an early disease (Fig. 7). Of the 
89 patients, 41 had FP. All the FP patients except one had early NB. Of the FP patients with 
negative or borderline anti-flagella IgG antibodies in the CSF, 59 per cent had positive IgG 
antibody responses to at least three of the new antigens in the CSF. In the patients with early 
NB, no difference was seen in the antigen responses, whether they had FP or other 
manifestations of NB.  
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Fig. 7. Results of IgG ELISAs with the recombinant antigens DbpA, BBK32, and OspC, and with IR6 peptide in 
the CSF, and serum of patients with duration of neurologic symptoms < 3 months and > 3 months. The levels of 
positivity for the OD/cut-off values (>1) are indicated by horizontal lines. The highest OD values for the variants 
of the indicated recombinant antigens were used in the analyses.  
OspC IgM ELISA seemed to perform better than anti-flagella IgM ELISA confirming early 
NB in the CSF. Both anti-OspC and anti-flagella IgM antibodies were highest in the patients 
with short duration of the disease. Seventy-two per cent of the CSF samples of the NB patients 
were positive for OspC IgG antibodies, 61% for IgM antibodies, and 81% for combined IgG 
and IgM antibodies. However, when the new panel of DbpA, BBK32, OspC, and IR6 antigens 
in IgG ELISA was used, IgM antibodies to OspC did not yield any further positive CSF 
identifications.  
 
Seropositivity to the new antigens concurred with positive immunoreactions in the CSF. Of the 
patients with antibodies to a given new antigen in the CSF, 77 to 98%, depending on the 
antigen, also had positive serum IgG antibodies to the respective antigen. Of the patients with 
undetectable CSF antibodies to a particular new antigen, 42 to 71% were positive for the 
respective antibodies in serum. 
 
To evaluate the risk of false-positivity with new antigens, we analysed the correlation between 
the number of new antigens positive in the CSF and the level of CSF anti-flagella IgG 
antibodies. Results positive for only one of the new antigens and negative for anti-flagella were 
suspected as false-positives. In our series, the number of such patients was limited to nine out 
of 89. These apparently false single test positivities occurred with various antigens 
stochastically. Additionally, four patients who were negative for both new antigens and anti-
flagella, were classified as true negatives. Thus, the total number of true positives used in 
calculating sensitivities for new antigens was 76 (89 minus these 13 true negatives).   
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5.4 SODIUM THIOCYANATE IN THE IgM SEROLOGY (III) 
In order to improve the binding specificity of IgM class antibodies in the ELISA using rOspC 
as an antigen, we tested agents known to dissociate interprotein interactions. The ability to 
differentiate LB from other diseases was monitored in experiments using urea, guanidine, or 
NaSCN as ingredients in the sample application buffer (BSA). In preliminary experiments with 
a small number of sera, thiocyanate was promising. Several concentrations of NaSCN (0.1 M 
to 2 M) were tested. The best discrimination between LB patient sera and EBV samples (false-
positives) was observed with 0.1 M NaSCN. No such effect was observed with NaSCN when 
flagella were used as the antigen, with either BSA or HSA as the sample application buffer 
(Table 9).  Depending on the rOspC used, the change in the OD values with or without NaSCN 
varied, and yet, with all the rOspCs, the effect was significantly greater with EBV than with 
LB patient samples (p<0.001). With other control samples, the change in OD resembled that in 
the LB patient samples. NaSCN decreased the number of false-positive EBV samples from 11 
to 7 of 17. Even more importantly, the values for the EBV samples remaining above the cut-off 
were all low positives only. Increasing the sodium chloride concentration instead of adding 
NaSCN to the serum dilution buffer did not significantly decrease the OD values of the EBV 
samples. 
Table 9. Decrease in the mean OD level (%) in the patient groups with LB, with EBV, and 
with negative controls (NC) by using 0.1 M and 0.5 M sodium thiocyanate (NaSCN).  
 OspC Flagella 
Patient group NaSCN 
(0.1 M)
NaSCN 
(0.5 M) 
NaSCN 
(0.1 M) 
NaSCN 
(0.5 M) 
LB 
n=10
5.0 39.2 29.2 70.1 
     
EBV 
n=7
29.5 52.3 15.8 45.4 
     
NC
n=8
19.7 39.2 16.9 43.4 
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6 DISCUSSION
 
6.1 GENERAL DISCUSSION
 
In this study, new methods of molecular biology have been utilised to develop new antigens for 
the serology of LB. The direct detection of Borrelia presents difficulties, as the sensitivities of 
culture and PCR are not sufficient. Thus, serological methods are mainly used for routine 
laboratory diagnosis. Because of the lack of a gold standard (positive culture) in the laboratory 
diagnosis, the diagnostic criteria of the patients based on clinical features and detectable 
antibodies to Borrelia may also be questionable. 
 
To increase the sensitivity and specificity above that of the current tests, the approach in this 
study was to use three variants of each new recombinant antigen to cover all three subspecies 
of B. burgdorferi sensu lato existing in Europe.  
 
6.2 IgM SEROLOGY (II, III, IV)
 
IgM serology has been used in the early stages of LB to diagnose EM or NB. The current tests 
using flagella or WCL as antigens have unsatisfactory sensitivities and specificities. Some viral 
infections and rheumatoid factor positivity may cause false-positive IgM reactions in several 
LB tests (Brown et al. 1999), a frequent problem with IgM antibodies in general. In EM, the 
diagnostic sensitivity of IgM serology does not exceed 50% (Hansen and Åsbrink 1989). Thus, 
new antigens with higher specificities and sensitivities are needed. 
 
OspC has been suggested to induce an early IgM response (Fung et al. 1994, Padula et al. 
1994, Magnarelli et al. 1996, Mathiesen et al. 1998a, Rauer et al. 1998, Wienecke et al. 2000). 
Moreover, promising results for EM patients with IgM WB using rFlaA as an antigen have 
been shown (Gilmore et al. 1999). In this study, IgM serology was used with rOspC and rFlaA 
antigens, in addition to flagella. In all stages of LB (EM, NB and LA), IgM serology with both 
rOspC and rFlaA concurred with that of flagella when all three variants of the recombinant 
proteins were used. Neither of the IgM ELISAs using rOspC, rFlaA or flagella was sensitive 
with EM patients. In order to compare WCL with flagella, antibodies to 41 kDa flagellar 
protein have been superior to WCL antigen in the serodiagnosis of LB (Coleman and Benach 
1987, Grodzicki and Steere 1988, Hansen et al. 1988, Steere 1988, Karlsson et al. 1990,  
Hansen et al. 1991).  
  
In this study, cross-reactive antibodies to FlaA reduced the specificity of IgM serology. With 
rOspC and flagella, IgM ELISAs were also complicated by false-positive reactions, although to 
a minor extent. To decrease the number of false-positive results, agents known to dissociate 
inter-protein interactions, such as urea, guanidine and NaSCN, were tested in rOspC ELISA 
experiments. NaSCN decreased the number of false-positive EBV samples, and those values 
for the EBV samples remaining above the cut-off value were low positives only. 
 
Intrathecal immune responses to recombinant antigens have rarely been studied in LB. 
Schutzer et al. (1997) have studied IgM reactivity in the CSF with rOspC from B. burgdorferi 
sensu stricto. Our results with CSF samples from a larger group of NB patients concurred with 
those of Schutzer et al. (1997). In the present study, rOspC IgM ELISA seemed better than 
anti-flagella IgM ELISA. False-positive reactions to rOspC were fewer in the CSF than in 
serum, possibly because of lower background reactivity in the CSF. 
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In conclusion, IgM responses to rFlaA and rOspC were at least as frequent as responses to 
flagella. However, owing to cross-reactive antibodies, rFlaA seemed to have a limited role for 
IgM serodiagnosis. 
6.3 IgG ANTIBODIES TO NEW RECOMBINANT OR PEPTIDE ANTIGENS IN THE
LABORATORY DIAGNOSIS OF LYME BORRELIOSIS (II, III, IV)
IgG serology has an essential role in the laboratory diagnosis of disseminated LB. The purpose 
of this study was to evaluate new specific antigens for the laboratory diagnosis of LB. To 
ensure a satisfactory sensitivity of the test, three pathogenic species of B. burgdorferi were 
individually applied in IgG ELISA.  
 
rFlaA appeared to be a sensitive antigen in IgG ELISA in the late stages of LB (74 to 79%). 
rOspC also had IgG reactivity (33 to 60%) in the late stages of the disease. The IgG response to 
rOspC during the later stages of LB has also been shown in other studies (Fung et al. 1994, 
Magnarelli et al. 1996, Mathiesen et al. 1998b, Magnarelli et al. 2000). Antibodies to flagella, 
however, exceeded the results of rFlaA and rOspC in the late stages of LB. For patients with 
EM, the sensitivity was equally unsatisfactory with rFlaA, rOspC and flagella. The variability 
of these results in individual antigens may be explained partly by sequence heterogeneity or by 
the different stages of the disease represented by the patient samples. B. burgdorferi FlaA is 
expressed at a considerably lower level than FlaB (the main part of the flagella). The surface of 
the borrelial flagella may have only a small amount of FlaA protein attached to the FlaB 
backbone, leaving a large part of the FlaB surface uncovered. This may account for the 
difficulty in finding specific IgM or IgG to FlaA.     
Another approach of this study was to use several recombinant or peptide antigens in parallel 
to increase the sensitivity of the test. A special interest was to examine the CSF of patients with 
NB. Recently, rDbpA has been suggested to be a sensitive and specific IgG antigen in late LB 
(Heikkilä 2002c) and rBBK32 both in early and late LB (Heikkilä 2002b). The IR6  peptide has 
been suggested to be a sensitive and specific antigen in ELISA (Liang et al. 1999b). Three new 
recombinant antigens, rDbpA, rBBK32 and rOspC, and the IR6 peptide were evaluated for 
diagnosis of NB in IgG ELISA. The antigens performed well and better than the flagella. 
Antibodies to the new antigens confirmed the positive NB diagnoses set by the anti-flagella 
antibodies. More importantly, of those NB patients negative or borderline for anti-flagella 
antibodies in the CSF, 51% were positive for at least three new antigens and 68% for at least 
two new antigens (mainly DbpA and IR6) in the CSF. Antibodies to rDbpA and IR6 peptide 
were observed in the CSF in early and late NB while antibodies to rBBK32 were detected 
mainly in early disease. Thus, the use of the new antigens at presentation of the disease 
improved the laboratory diagnosis of NB. The results suggest that antibody positivity in the 
CSF to at least two new antigens could be used as a confirmatory laboratory marker for NB. 
Furthermore, antibodies to BBK32 might be suggested as a marker of an early LB.    
 
This study shows that, in European conditions, because of sequence heterogeneity between 
species, recombinant proteins from all three subspecies or at least from B. afzelii and B. garinii 
are needed in the laboratory diagnosis of LB to cover all the relevant borrelial species. Further 
studies are needed to evaluate the usefulness of a combination of these and/or other antigens. 
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6.4 SEQUENCE DIFFERENCES OF FLAGELLIN A AND OspC FROM DOMESTIC
BORRELIAL STRAINS (II, III)
Sequences of FlaA protein were highly homologous, having identity of 95% within the three 
domestic strains of B. burgdorferi sensu lato. Of two other published FlaA sequences, strain 
B31 was identical with our B. burgdorferi sensu stricto ia. OspC was more heterogeneous, with 
protein sequence identities varying between 57 and 73%. A comparison of other OspC strains 
with close homology published in the GenBank showed identity between several other 
European published and domestic OspC sequences of a given B. burgdorferi sensu lato species.  
 
Because of the predominance of IgG immune reactions against OspC from B. afzelii, it is likely 
that, with time, the maturation of the IgG immune response would direct the specificity of the 
antibodies preferentially towards the epitopes of the immunizing strain. The high prevalence of 
B. afzelii in Scandinavia may account for this finding (Junttila et al. 1999).  
  
In spite of the strong homology of FlaA proteins within Borrelia genospecies, recombinant 
proteins from B. garinii and/or B. afzelii perfomed better than B. burgdorferi sensu stricto in an 
ELISA format. Obviously, various FlaA proteins have both common and divergent antigenic 
epitopes. In view of the heterogeneity of OspC, a polyvalent antigen with several variants from 
at least B. afzelii and B. garinii should be preferred when rOspC or rFlaA are used in the 
serodiagnosis of LB in Europe. Therefore, the OspC used as a vaccine candidate was also 
chosen as a polyvalent vaccine consisting of recombinant proteins from several subspecies and 
strains of B. burgdorferi sensu lato (Wahlberg 1999). 
6.5 MARKERS OF LYME DISEASE ACTIVITY (I)
One difficulty in making the laboratory diagnosis of LB has been the absence of a marker to 
distinguish between active disease and successfully treated LB. Serum immune complexes 
specific for B. burgdorferi have been suggested to confirm early and/or active LB (Schutzer et 
al. 1999, Brunner and Sigal 2001). Levels of antibodies to the IR6 peptide have been said to 
diminish after successful treatment (Philipp et al. 2001) but contradictory results have also 
been reached in attempts to confirm the IR6 results in independent laboratories (Heikkilä et al. 
2002a, Peltomaa 2002).  
 
In this study, serum levels of flagella and combined sonicate IgG1+3 subclass antibodies were 
determined during a 1 to 2 year follow-up period after the start of treatment of late LB. The 
results suggest that a rapid decrease in flagella antibodies may serve as a marker of successful 
treatment of LB. A decrease in the titre to half that of the pre-treatment level during a 6-month 
period suggests eradication of the disease. This goes both for NB and LA. In the case of a 
slower decrease in antibodies, the situation remains unclear. The faster decrease of anti-flagella 
antibodies compared with those against sonicate may be associated with the nature of flagellar 
antigenic structure with repeating surface determinants. This property may be related to the 
rapidity of the antibody kinetics. The most prominently decreasing flagella IgG subclass was 
IgG1. The study suggests a 6-month post-treatment examination for analysing the kinetics of 
the flagella antibody response. The 3-month post-treatment sample is also valuable, since the 
immune response to the antigen load may increase for up to three months. For clinical 
purposes, a more rapid method for demonstration of cure would be appreciated. 
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CONCLUSIONS
 
 
ELISA is the method most commonly used for the serodiagnosis of LB. However, routine 
ELISAs with flagella or WCL as antigens do not have optimal sensitivity or specificity. 
Another drawback of these tests is that there is no realiable marker to indicate an active LB or 
successful cure. This has led to a search for new antigens and to the development of 
recombinant and peptide antigens. A sensitive and specific laboratory diagnosis is also 
essential because of the rigours of antibiotic treatments, especially in cases of late LB. 
 
This study showed that, after successful treatment of late LB, the half-lives of IgG flagella 
antibodies were significantly shorter than those of WCL antibodies. The results suggest that a 
decrease in titre to half that of the pre-treatment level during a 6-month period may be used as  
a marker of successful treatment response and eradication of the disease. 
 
The amino acid sequences of the three FlaA proteins were highly homologous. For IgG 
serodiagnosis of NB and LA, rFlaA appeared to be a sensitive antigen. The OspC sequences 
were more heterogeneous. IgM ELISA with rOspC performed better in the early stages of LB 
and IgG ELISA in the late stages of the disease. The immunoreactivities in sera of Finnish 
patients were stronger against rFlaA and rOspC from B. garinii and B. afzelii than those from 
B. burgdorferi sensu stricto. Cross-reactivity to EBV infections in IgM ELISA could be 
reduced by using thiocyanate in the serum dilution buffer. In the European context, if borrelial 
proteins are used as antigens in the serology of LB, sequence heterogeneity between species 
implies that variant proteins are needed to cover all the relevant borrelial species.  
 
In the study of NB, three variant recombinant antigens, DbpA, BBK32, and OspC, and B. 
garinii type IR6 peptide, seemed to improve the CSF-based laboratory diagnosis compared 
with that of a commercial flagella antigen. The results suggest that antibodies to BBK32 may 
be useful markers of an early LB. New antigens also performed well in the serum analyses but 
the discriminatory power between patient and control samples was better in the CSF than in 
serum. In the light of this study, assessment of antibodies to several Borrelia-specific antigens 
in parallel seems to increase the accuracy of the laboratory diagnosis of LB. 
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